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Abstract: Co-crystals are emerging as a potential area in the field of crystal designing as it 
improves material’s physicochemical properties. Many groups are working on the 
development of newer techniques for the preparation of co-crystals, which can be scalable 
and contribute to the green agenda. Being continuous and scalable technique, our own 
developed twin screw extrusion mediated solvent free continuous co-crystallisation (SFCC) 
technique has been used for the preparation of carbamazepine: saccharin co-crystal. 
Carbamazepine has been used as a model drug since it shows challenges such as low 
solubility (BCS class II), polymorphism and thermolabile nature whilst, saccharin was used 
as a co-former.  
Effect of extrusion processing parameters such as shear, temperature and screw speed on co-
crystallisation has been studied. In addition to this, effect of particle size of co-crystal 
components, use of hydrated form of carbamazepine, addition of solvent and application of 
reverse elements on the purity of co-crystal was understood. Use of carbamazepine dihydrate 
as a starting component yields pure co-crystals. The addition of small amount of polar solvent 
in anhydrous carbamazepine also yields pure co-crystals whereas particle size did not show 
any significant effect. Result showed that selection of processing temperature near to eutectic, 
moderate shear and increase in residence time of component mixture in mixing zone was 
mainly responsible for co-crystallisation. The extrudates were mainly characterised by 
XRPD, DSC and in-vitro dissolution tests. Pure co-crystals prepared by addition of highly 
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polar solvent have been showed drug release identical to that of pure co-crystals prepared by 
solvent crystallisation.  
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__________________________________________________________________________________ 
Chapter 1: Introduction 
======================================================================= 
 
Co-crystallisation is presently recognised as an important technique to prepare single 
crystalline forms of compound where substitutes to salts/polymorphs are desired. Co-
crystallisation provides an opportunity to improve physico-chemical properties of the 
material which have particular interest in clinical relevance. Previously reported case studies 
demonstrated successful improvement in solubility (Good et al., 2009), bioavailability 
(Remenar et al., 2009) and stability (Trask et al., 2006) etc. In the case of pharmaceutical 
compounds which do not possess ionisable groups, where salt formation is not possible, co-
crystallisation may be utilised.   
Pharmaceutical co-crystals are achieving great interest and subsequently, various techniques 
for co-crystallisation have been developed. Such techniques involve solvent crystallisation, 
slow evaporation, solid-state grinding (neat grinding and solvent drop grinding), slurry 
crystallisation and sono-crystallisation etc. Solution based co-crystallisation techniques are 
difficult, non-continuous and require large amounts of solvents. It also encompasses the 
possibility of crystallisation of a single component phase and hence purity is an issue.  Solid-
state co-crystallisation for e.g. grinding, solitary or in presence of a very small amount of 
solvent offers enormous capability to prepare co-crystals and has advantages in regard to high 
yield, environmental friendly, low cost and ease of screening etc.   
Nowadays, pharmaceutical scientists are attracted towards solid-based continuous co-
crystallisation processes. Shan and Zaworotko also appreciated the potential of solid based 
techniques for preparation of co-crystals ((Shan and Zaworotko, 2008). Various mechanisms 
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were illustrated in previously reported case studies to elaborate solid-state grinding derived 
co-crystallisation. Chadwick et al. demonstrated the formation of co-crystals at ambient 
temperature along with the importance of intermediate metastable eutectic liquid phase which 
drives intermolecular mass transfer that results in the generation of co-crystals (Chadwick et 
al., 2007). However, Rastogi et al. suggested vapour diffusion as a mass transfer mechanism 
during solid-state grinding. They concluded that in the grinding process, induced shear 
increases the surface area of the starting crystalline component. Currently, grinding and 
solvent evaporation are the most common techniques for co-crystallisation, although, these 
techniques have scale-up limitations and batch process variations and are hence suited for 
small scale-screening operations. To overcome these limitations, development of a novel 
shear dependent co-crystallisation process is necessary to provide solvent free continuous co-
crystallisation. This technique should be suitable for large scale manufacturing. Recently, our 
group has patented a solvent free continuous co-crystallisation (SFCC) technique using hot 
melt extrusion (Paradkar et al, 2010) which has been successfully used for preparation of 
ibuprofen: nicotinamide co-crystals (Dhumal et al., 2010). SFCC has the potential to produce 
co-crystals in agglomerated form which are suitable for direct compression which skips 
downstream processing steps. It has been proved that a combination of shear deformation and 
controlled heat gives rise to co-crystallisation and hence, there is further need to understand 
the process in respect to the effect of different process variables.  
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Following are the aims and objectives of the project. 
? The key aim of this project is to achieve solvent free continuous co-crystallisation 
(SFCC) by means of twin screw extruder (TSE) and explore the underlying mechanism of 
SFCC process.  
? Specific objectives include: 
? To explore different process variables which affect co-crystallisation derived by TSE. 
Exploring process variables include optimum processing temperature, screw configuration 
which provides prerequisite shear intensity, residence time etc.  
Carbamazepine (CBZ) was selected as a model drug and saccharin (SAC) as a co-former. 
Carbamazepine has been found in four different anhydrous polymorphs, while its co-crystal 
with saccharin exists in two different polymorphs and hence served as an ideal compound 
which gives opportunity to study polymorphism and new crystalline structures. The 
emergence of carbamazepine: saccharin (1:1) co-crystal (CBZ: SAC) as a new drug 
application in pharmaceutical market is in progression which is supported by published non-
finalised draft guidance by the U.S. Food and Drug Administration (U.S.F.D.A.). 
Carbamazepine: saccharin (1:1) co-crystal is proven to be successful at in-vivo studies and it 
has been found that co-crystal exhibit higher plasma level than marketed formulation 
Tegretol (Hickey et al., 2007). Carbamazepine is a drug which is classified as a BCS class II 
drug, possessing poor water solubility which is a rate determining step for such an API. Thus, 
further study of dissolution enhancement of such a compound is essential.   
Non-covalently bonded carbamazepine: saccharin (CBZ: SAC) co-crystal was selected as a 
model co-crystal system since its crystalline structure and polymorphic forms are well 
known. Furthermore, functional groups present in carbamazepine and saccharin are 
frequently detectable in other pharmaceutical compounds. 
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? To explore process modification necessary to achieve co-crystallisation 
Processing of a thermo-labile drug in twin screw extrusion (TSE) is considered as a 
challenge. Process modification include study of additional processing variables such as 
utilizing the hydrate form of active pharmaceutical ingredient (API) as a starting component, 
effect of particle size of crystalline component, addition of different solvents on the purity of 
co-crystals in twin screw extrusion (TSE) mediated co-crystallisation. 
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__________________________________________________________________________________ 
Chapter 2: Background 
======================================================================= 
2.1 Background 
Solubility is a mass transfer process, recognised as a phenomenon of dissolution which 
results in formation of a homogenous phase (Vemula et al., 2010). Solubility of a drug is 
considered as an important factor in formulation development because it is directly related to 
pharmacological response.  Poor water soluble drugs need to be administered in high dosage 
to attain the desired therapeutic concentration in systemic circulation (Vemula et al., 2010).  
For absorption of drug, it should be present in an aqueous solution at the site of absorption 
and therefore, aqueous solubility is always considered as a challenge in formulation 
development (Vemula et al., 2010). 
2.1.1 Approaches for solubility enhancement 
Progress in pharmaceutical sciences has resulted into establishment of various solubility 
enhancement approaches. These strategies include some formulation techniques and crystal 
engineering techniques. Formulation techniques include pH adjustment of the dissolution 
medium for solubilisation of drug, micronisation for increasing the surface area, dissolution 
of drug using co-solvents, complexation using cyclodextrins etc (Sharma et al., 2010). The 
pH adjustment and co-solvency technique has limitations of uncontrolled precipitation after 
dilution (Vemula et al., 2010). Complexation technique has limitations of solubility 
enhancement for drugs having low solubility to start with (Sharma et al., 2010). 
Micronisation increases solubility by increasing surface area but at the same time keeping 
equilibrium solubility constant. When the particle size is reduced to a sub-micron level, high 
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surface charge gets emitted on distinct small particles which encourage them to be converted 
into agglomerates that cause difficulty in the development of solid dosage form (Vemula et 
al., 2010). Crystal engineering strategies can be potentially used to a wide range of crystalline 
pharmaceutical compounds. It has been reported that crystal engineering strategies served as 
an alternative for traditional techniques for solubility enhancement and subsequent 
bioavailability. Crystal engineering techniques involve modification of molecular solids by 
improving their inherent properties which can be done by changing surface or molecular 
assembly (Blagden et al., 2007). The following are some of the crystal engineering 
approaches for solubility enhancement. 
2.1.1.1 Salt formation  
Salt formation is a conventional approach for modification of active pharmaceutical 
ingredients (APIs) properties and solubility enhancement. During salt formation, the API 
undergoes acid-base reaction and the resulting pharmaceutical API possesses either basic or 
acidic functionality. Salt formation is a result of proton transfer from either base or acid and it 
is dependent on pKa value of the components. During salt formation, the API and counter-ion 
gets connected with strong ionic bonds. The limitation of salt formation approach is its 
suitability for those pharmaceutical compounds which possess acidic or basic ionisable 
groups.  
2.1.1.2 Hydrates and solvates  
During crystallization, liquid gets incorporated into the crystal structure by hydrogen bond 
formation to become a solvate/hydrate of the API. A crystal form which contains either 
stoichiometric or non-stoichiometric proportion of the solvent is termed as a solvate whereas, 
a solvate which contain water as a solvent is termed as hydrate.  It has been mentioned that 
one third of total pharmaceutical compounds have the potential to undergo hydrate formation 
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(Jones et al., 2006). Concerning water solubility, the anhydrous form of compound is 
generally more water soluble than the corresponding hydrate, (Bartolomei et al., 2005) since 
in hydrates, the interaction between API and water molecule results in further thermo-
dynamical stability (Puigjaner et al., 2010). For example, the hydrate form of diclofenac 
sodium is less water soluble than its anhydrous form. Haiyan et al also demonstrated high 
water solubility of the anhydrous form of carbamazepine (CBZ) compared to carbamazepine 
dihydrate (CBZ: 2H2O) (Haiyan et al., 2006). There are some exceptions where hydrates 
showed more solubility than their anhydrous form, for example, zwitterionic hydrate of 
norfloxacin showed higher solubility than its anhydrous form (Puigjaner et al., 2010). 
Hydrates get converted into the anhydrous form during processing because of induced 
stresses like variations in temperature, pressure, humidity etc which limit its application. As a 
result, the physical properties of the dosage form changes significantly. Solvates are well 
known as pharmaceutical products, since they have successfully demonstrated solubility 
enhancement of various crystalline steroids, xanthenes and other solid drugs (Shefter and 
Higuchi, 2006). However, solvates have some limitations being biologically toxic in nature. 
Hence, solvate formation approach is avoided for tailoring solid state forms of APIs.  
2.1.1.3 Amorphisation  
The amorphisation technique leads to dissolution enhancement by preparing the crystalline 
compound into a high energy metastable amorphous compound (Babu and Nangia, 2011). 
The amorphous state exists as super-cooled glassy state having random orientation of 
molecules. Amorphous drugs contain low density, high free energy and lesser particle size 
that improves wettability (Babu and Nangia, 2011). But during dissolution, the metastable 
amorphous compound is converted into a stable crystalline compound resulting in a “spring-
parachute effect” (Babu and Nangia, 2011). Thus, amorphous compounds demonstrate peak 
solubility for a shorter period of time. As the amorphous compound is present in its 
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metastable state, it easily gets transformed into crystalline form; hence, storage stability is 
also an issue. 
2.1.1.4 Polymorphism  
It is known that during the drug development process, crystalline polymorphs having the 
lowest energy are preferred by innovator pharmaceutical companies as it is physically and 
chemically stable, shows reproducible bioavailability and excellent storage stability (Singhal 
and Curatolo., 2004).  But in exceptional conditions, the metastable polymorph has been used 
where the lowest energy polymorph is unstable because of adjacency of two reactive groups 
in a crystal lattice (Singhal and Curatolo., 2004). Some pharmaceutical APIs show 
polymorph-dependent absorption rate, for example, polymorph B of chloramphenicol 
palmitate demonstrates a higher dissolution rate than polymorph-A in humans (Aguiar et al., 
1967). There are some other drugs which have shown polymorph-dependent bioavailability 
such as amobarbitol (Kato and Kohketsu, 1981), cimetidin (Kokubo et al.,1987), 
chlortetracycline (Miyazaki et al., 1974) etc. Liebenberg stated that polymorph A of 
oxytetracycline provides approximately 55% drug release in first 30 minutes while, other 
polymorphs show around 95% drug release in the same time  (Liebenberg et al., 1999).  
Though polymorphism has been successfully proved as an excellent approach for solubility 
enhancement, it has some limitations. Stability of metastable polymorphs is an issue as it may 
convert into the most stable form during storage. Thus, physical and chemical modification is 
a prime necessity for real-time storage (Singhal and Curatolo., 2004). At present, it is difficult 
to predict observable number of polymorphs computationally, even for a simplest molecule 
(Jones et al., 2006). To search and develop the lowest energy polymorph is a tedious and 
time-consuming process. 
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2.1.1.5 Co-crystallisation  
All the above techniques for solubility enhancement of drugs encompass various limitations. 
But nowadays, a new promising approach called co-crystals is available to enhance the 
solubility of poorly soluble APIs. Co-crystals are molecular complexes in which the poorly 
soluble API and co-former held together in stoichiometric ratio by hydrogen bonding. For 
compounds having weak ionisable groups and neutral APIs, it serves as an alternative option 
to salt formation, hydrates or solvates. 
There are various pharmaceutical APIs which are categorized under the biological 
classification system (BCS) class II having good therapeutic efficacy however, have less 
marketed value because of their poor physicochemical properties such as solubility, 
dissolution rate, moisture induced phase transformation, stability etc (Sekhon et al., 2009). 
Co-crystals have gained attention of pharmaceutical scientist by shifting the physical and 
chemical properties of APIs and also serve as a remarkable alternative to salts for non-
ionisable APIs (Sekhon et al., 2009). BSC class II drugs have poor solubility and hence 
dissolution which can be addressed by pharmaceutical co-crystallisation of such an API with 
hydrophilic co-former. For example, carbamazepine shows a significant improvement in 
dissolution rate and hence bioavailability in dogs after co-crystallisation with saccharin (Shan 
and Zovorotko, 2008). The co-crystallisation technique also improves stability of APIs which 
are sensitive to moisture induced phase transformation. Even co-crystals are applicable for 
APIs having high molecular weight. For example, high molecular weight itraconazole can 
form a co-crystal with succinic acid (Jones et al., 2006) and malic acid (Yadav et al., 2009). 
Hydrogen bonding is a key element behind molecular recognition and design of molecular 
assemblies which is responsible for generation of co-crystals having molecular networks with 
a single API or API along with co-former. Hydrogen bonds are responsible for producing 
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different families of molecular networks with different molecular components to form hetero-
synthons.  So there is a wide scope for an API to form co-crystal with many co-formers and 
exhibit a wider range of diversity in dissolution, stability and solubility parameters. Hence, 
there are legal issues and challenges for patent protection, if the co-crystal possesses any 
clinical advantage (Shan and Zovorotko, 2008).  
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2.2 Co-crystallisation 
The crystalline form of an API is the vital part as far as the performance of dosage form is 
concerned. Delivery in the form of a single solid dosage form is considered to be convenient 
with respect to stability and reproducibility especially when formulation is composed of a 
single crystalline form of an API (Shan and Zovorotko., 2008). It means that for an API the 
specific ‘crystal form selection’ is a fundamental step which is very vital for legal, clinical 
and regulatory perception. This chapter highlights the introduction of co-crystals and its 
definition, applications of co-crystals, methods of preparation, characterisation of co-crystals 
and challenges in co-crystallisation. 
Co-crystals are an emerging class of crystal forms considered as a radical phase in chemical 
crystallography and crystal engineering.  A key focus of crystal engineering is to prepare 
multi-component crystals for example, hydrogen bonded synthons.  
2.2.1 What are co-crystals?  
Interestingly, the exact definition of co-crystals has been controversial. After a survey of 
evidence in Web of science, co-crystals have been termed as a molecular complex, molecular 
adduct, lattice adduct, inclusion and channel compound, multi-component molecular crystal, 
solid-state complex, hetero-molecular crystal and organic molecular crystal (Zukerman-
schpector and Tiekink., 2008).  Desiraju (2010) has expressed his concerns over the 
definition of co-crystal and has mentioned that multi-component crystals with clearly defined 
intermolecular, i.e. non-covalent, interactions between the component molecules termed as 
molecular complex (Zukerman-schpector and Tiekink 2008, Desiraju 2010). Whereas, J.D. 
Dunitz in 2003 suggested that the term co-crystal includes the full range of multi-component 
crystals which encompasses solvates, channel compounds, clathrates, etc. (Dunitz, 2003).  
It can be concluded that although there are disagreements, almost all researchers agree to a 
view that co-crystals are composed of more than one component. But a more restrictive 
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definition was stated in 2008 by Shan and Zaworotko, “...cocrystal is a multiple component 
crystal in which all components are solid under ambient conditions when in their pure form. 
These components co-exist as a stoichiometric ratio of a target molecule or ion and a neutral 
molecular cocrystal former(s)” (Shan and Zaworotko, 2008). Stoichiometric ratio is the 
amount of co-crystal components which has to be more or at least equal to that of allowed 
additive level such that the required therapeutic level of the API will have to be balanced with 
the level of active API (Blagden et al., 2008). It is an important practical consideration that 
each component in the co-crystal should be present in solid state. There are many counter 
molecules which are regarded as a “GRAS- Generally Recognised As Safe (U.S. Food and 
Drug Administration’s GRAS List)” having potential to incorporate in a crystal lattice of host 
molecules during co-crystallisation (Sekhon 2009, Jones et al., 2006).  
According to the USFDA, co-crystals are “...solids that are crystalline materials composed of 
two or more molecules in the same crystal lattice.” (U.S. Food and Drug Administration’s 
Guidance for Industry: Regulatory classification of Pharmaceutical Co-crystal.) 
2.2.1.1 USFDA guidelines for Co-crystals 
According to the USFDA, for applicable novel drug applications (NDAs) or abbreviated new 
drug applications (ANDAs) claiming to have co-crystal form, it has been also recommended 
that  
1.“Determine whether, in the crystalline solid, the component API with the excipient 
compounds in the co-crystal exist in their neutral states and interact via non-ionic 
interactions, as opposed to an ionic interaction, which would classify this crystalline solid as 
a salt form. Generally speaking, if the API and its excipient(s) have a ΔpKa (pKa (base) - 
pKa (acid)) < 0, there will be negligible proton transfer and the molecular complex will be a 
co-crystal. If the ΔpKa > 3, there will be complete proton transfer resulting in complete 
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ionization and formation of a salt as opposed to a co-crystal. In instances where the ΔpKa > 
0 and ΔpKa < 3, the extent of proton transfer and ionization is generally not predictable.”  
2. “For pharmacological activity, ensure that the API dissociates from its excipient prior to 
reaching the site of action.” (U.S. Food and Drug Administration’s Guidance for Industry: 
Regulatory classification of Pharmaceutical Co-crystal.) 
 
It has also been mentioned that “If these two pre-conditions are met in this manner, an API 
that has been processed with a co-crystallizing excipient to generate an “API—excipient” co-
crystal should be treated as a drug product intermediate. As a drug product intermediate, the 
co-crystal is defined and controlled as part of the drug product in terms of, for example, 
formulation ingredients, solid state form, manufacturing process, and performance, but the 
API is still the same.  Co-crystal containing drug products (as defined in this guidance) will 
not be considered to contain new APIs, but rather to contain a specifically designed 
formulation component called a co-crystal drug product intermediate that is expected to 
contribute to improved drug product performance (e.g., solubility, dissolution).” (U.S. Food 
and Drug Administration’s Guidance for Industry: Regulatory classification of 
Pharmaceutical Co-crystal.). 
 
Figure 2.1 shows the possibilities of crystalline patterns for an API. Forms (a) and (b) can be 
obtained from crystallisation of an API. When a crystal form contains water it can be termed 
a hydrate and when it contains any solvent other than water then it is termed a solvate. 
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[Fig. 2.1 Six possible crystalline forms for an API- a) Single API b) Polymorph of API C) 
Clathrate hydrate/ solvate of API d) Hydrate of API e) Salt of API f) Pharmaceutical Co-
crystal from Shan and Zovorotko, 2008] 
Co-crystallisation via non-covalent or hydrogen bonding of an API with a co-former in 
stoichiometric ratio leads to formation of co-crystals. Unlike co-crystallisation, proton 
transfer takes place in salt formation which serves as a benefit of co-crystal over salt 
formation because it possesses potential to adapt properties of both ionisable and non-
ionisable compounds. 
2.2.2 Application of co-crystals 
Co-crystals provide opportunities to tailor physico-chemical properties of the molecule 
without making or breaking of covalent bonds (Shan and Zavorotko., 2008). In co-
crystallisation, irrespective of pharmaceutical profile (ionisable, acidic, basic functional 
groups), an API undergoes co-crystallisation to form multi-component assembly (Blagden et 
al., 2008). Co-crystals offer great opportunity for the compound which does not possess 
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ionisable groups and hence are unable to undergo salt formation, which is an important 
application of co-crystallisation. Zerkowski et al., in 1992 studied more than 60 co-crystals 
which were then structurally characterised in various studies and into ones that demonstrated 
potential divergence of forms in which APIs can exist (Zerowski et al., 1992). 
Pharmaceutical co-crystals enhance properties of API such as stability, solubility, 
bioavailability and compressibility etc. 
Some chosen case studies are discussed further which demonstrate the application of co-
crystallisation for changing the physico-chemical properties of clinical relevance in APIs. 
Carbamazepine, an important anti-epileptic drug possesses low solubility and hence is 
classified under BCS class II drugs. It needs to be administered in high dosage for achieving 
the desired therapeutic effect because oral administration encompasses some challenges such 
as poor solubility, dissolution limited bio-availability and auto-induction etc (Shan and 
Zavorotko., 2008). The anhydrous form of carbamazepine is less stable. It easily undergoes 
moisture induced phase transformation to form carbamazepine dihydrate. After co-
crystallisation of carbamazepine with saccharin, the resulting co-crystal showed considerably 
improved physical stability (Hickey et al., 2007). Furthermore, carbamazepine: saccharin co-
crystal (1:1) showed enhanced dissolution properties and pharmacokinetics in a dog model. It 
has been demonstrated that CBZ: SAC co-crystal possesses higher Cmax and equal Tmax 
compared with the marketed form Tegretol (Hickey et al., 2007). Hence, it can be concluded 
that CBZ: SAC co-crystal proved to be superior to other forms of carbamazepine in context 
of stability, solubility and oral absorption profile in dogs.  
Co-crystallisation is also suitable for salts of APIs. The availability of salts of API in the 
pharmaceutical market is well known. Recently, an approach to develop co-crystals with 
chloride salts of APIs for example, fluoxetine hydrochloride is emerging. Fluoxetine 
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hydrochloride is an antidepressant drug which has been successfully co-crystallised with 
three different co-formers namely with benzoic acid (1:1), with succinic acid (2:1), and with 
fumaric acid (2:1). Within those three co-crystals, fluoxetine HCl: succinic acid (2:1) co-
crystal showed a two fold increase in aqueous solubility within five minutes (Childs et al., 
2004). The important aspect of this study is that by simply non-covalent hydrogen bonding, 
salt of API can also generate co-crystals which can generate a characteristically diverse 
dissolution profile.  
In another case, formation of itraconazole co-crystal with l-malic acid exhibits identical 
bioavailability as compared to its marketed amorphous formulation. Itraconazole is a triazole 
antifungal agent which is administered via both intravenously and orally (Remenar et al., 
2003). It is marketed as a Sporanox capsule in which the amorphous form of itraconazole is 
coated on sucrose beads for oral administration. It needs to be administered along with 
acidified β-cyclodextrin to achieve maximum absorption (Remenar et al., 2003) which results 
in diarrhea. Thus, to reduce these problems co-crystallisation of itraconazole was carried out 
with l-malic acid. It was noted that co-crystals of itraconazole showed identical dissolution 
profile to that of Sporanox (Remenar et al., 2003). Furthermore, in pharmacokinetic studies 
using a dog model, co-crystals of itraconazole demonstrated identical oral bioavailability to 
Sporanox (Remenar et al., USP20050070551). Thus, without compromising stability and 
crystallinity, pharmaceutical co-crystals have demonstrated solubility and bioavailability 
enhancement.  
Karki et al. in 2009 have demonstrated increase in compressibility of paracetamol by using 
co-crystallisation approach. Polymorph-I of paracetamol is metastable in nature. It is poorly 
compressible and requires large amount of binders during tableting. Co-crystallisation of 
paracetamol with theophylline showed increase in compressibility (Karki et al., 2009). 
Dhumal et al., in 2010 demonstrated single step co-crystallisation by means of hot melt 
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extrusion which is a solvent free continuous co-crystallisation (SFCC) technique. SFCC 
prepares co-crystal in the form of agglomerates which are directly compressible. 
Furthermore, it prevents APIs which are susceptible to process induced polymorphic 
transformation. Other solid state co-crystallisation techniques (for example, grinding) offer 
enormous potential with respect to green chemistry by decreasing the use of solvents and 
increasing yield (Shan and Zavorotko., 2008).  
In this way, co-crystallisation provides opportunity to APIs by enhancing their solubility, 
stability and bioavailability. 
2.2.3 Methods of preparation 
As shown in following figure 2.2, there are various techniques for preparation of co-crystals 
based on the absence and association of solvents in co-crystallisation. Solvent based co-
crystallisation methods were sub-divided into four techniques - solvent crystallization, slurry 
conversion, cooling crystallisation, precipitation, (Yadav et al., 2009). For solvent 
crystallisation, two components which bear identical solubility must have been added in 
specific stoichiometric ratio into the mixture of solvents. The process of solvent 
crystallisation comprises formation of heated, supersaturated solution of the drug and gradual 
cooling. This leads to nucleation and further mass transfer of the solute from liquid solution 
to a pure solid crystalline phase, resulting in crystal growth. Hence, crystallisation is a 
phenomenon associated with change in the transient solubility of the solute in the given 
solvent, change in temperature or other factors, unlike the precipitation resulting from a 
chemical reaction. But it is crucial to assure that similar solubility alone results in the 
outcome of co-crystal (Yadav et al., 2009). It has been recommended that if co-crystallising 
components exhibit polymorphism, the opportunity of formation of crystal packing gets 
increased which results in a wide range of different packing arrangements and structural 
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flexibility (Yadav et al., 2009). Thus, co-crystallisation is a result of non-covalent bonding of 
complimentary functional groups having the ability to form hetero-synthons. 
 
                      [Fig.2.2 Classification of preparation methods of co-crystals]  
For solvent based co-crystal screening, the second type is slurry conversion which is 
considered as a rational technique (Takata et al., 2008). It has been reported that slurry 
conversion can be employed to analyse whether the co-crystal or polymorph is 
thermodynamically stable or not (Takata et al., 2008). The method includes solubilising the 
crystalline components in different organic solvents along with water in stoichiometric ratio 
and to evaporate the solvents to achieve supersaturation in slurry form. The solvent in slurry 
is then decanted to separate co-crystals (Yadav et al., 2009). Ultrasound co-crystallisation can 
be applied to wet solid mixtures in which co-crystal formation is achieved by the utilisation 
of ultrasound energy (Yadav et al., 2009). In cooling crystallisation, the mixture of crystalline 
components and solvent is directly heated at elevated temperature for a short period of time, 
unlike gradual heating in solvent crystallisation to dissolve components for achieving super-
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saturation. In this approach, the mixture constantly experiences gradually controlled cooling 
which leads to formation of co-crystals through re-crystallisation (Morissette et al., 2004). In 
precipitation, co-crystal formation is achieved by mixing crystalline co-crystal components in 
non-stoichiometric concentrations into a mixture of solvent (Rodriguez-Hornedo., 2005) in 
accordance to solubility product behaviour. 
Solid based methods have gained importance since as they serve as an alternative approach to 
solution based crystallisation techniques (Trask et al., 2004). Since, these minimize excessive 
utilisation of crystallising solvents, they have been considered as “green” techniques. Solid 
state grinding in addition, offers the advantage of higher yield and ease of experimental 
design. Grinding is split into two divisions: neat grinding and solvent assisted grinding. Neat 
grinding can be achieved manually by mortar-pestle and mechanically with a mixer mill 
(Trask et al., 2006). Liquid assisted grinding involves insignificantly small additions of 
solvent having appropriate polarity for enhancement of co-crystallisation kinetics (Trask et 
al., 2004). Solvent assisted grinding affords an additional degree of freedom which results in 
enrichment of molecular collisions (Shan et al. 2002, Chadwick et al, 2007).  
2.2.4 Characterisation of co-crystals 
There are several techniques to characterise co-crystals. Mainly pharmaceutical co-crystals 
are characterised by two ways according to chemical structure and physical properties. For 
structural determination of co-crystals techniques such as infrared spectroscopy, Raman 
spectroscopy, single crystal X-ray crystallography and Powder X-ray diffraction techniques 
are employed (Sekhon., 2009). X-ray diffraction is used to check whether crystalline material 
is generated or not (Schultheiss and Newman., 2009). It also provides XRD-patterns for co-
crystallising components and helps to differentiate them from the obtained final product, 
depending on the crystal structure and molecular arrangements. When a pharmaceutical API 
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generates a co-crystal with co-former, the XRD pattern gets altered because placement and 
non-covalent bond formation occurs. Thus, co-crystals show different characteristic peaks in 
comparison to the co-former and API. IR-spectroscopy and Raman spectroscopy are the 
vibrational spectroscopic methods which play a vital role in the determination of chemical 
structure and hydrogen bonding between co-former and pharmaceutical API. The inter-
molecular interactions that generate co-crystals are also present in single-crystalline 
components. For differentiating hydrogen bond interactions in crystalline components and in 
co-crystals, IR-spectroscopy serves as an excellent technique (Jaysankar et al., 2006). Raman 
spectroscopy can be also utilized for determination of polymorphism in starting components 
and resulting co-crystals.  
Thermal analysis is employed for determination of physical properties such as melting point 
and degradation. Thermal analysis is accomplished by differential scanning calorimetry 
(DSC) and thermo-gravimetric analysis (TGA). DSC thermogram provides information about 
heat flow through the material from which it is easy to identify whether the material is 
crystalline or not. Crystalline compounds show physical properties like melting point and re-
crystallisation, while amorphous compounds show glass transition. Polymorphs exhibits 
different melting points and hence DSC helps in characterisation of co-crystals. So, DSC 
plays important role in qualitative analysis of co-crystals as purity of compounds can also be 
analysed from it. 
Thermo-gravimetric analysis is used to determine onset of degradation of material and thus it 
is used in pre-formulation studies, which also helps to determine processing parameters. 
Scanning electron microscopy (SEM) is employed for microscopic study of crystals such as 
surface properties, crystal size and shape. Solid state nuclear magnetic resonance (NMR) 
easily determines non-covalent interactions between co-crystals and proton transfer in salt 
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formation and hence helps in distinguishing co-crystals and salts (Schultheiss and Newman., 
2009). 
2.2.5 Challenges in co-crystallisation 
Co-crystallisation is facing various challenges in the context of purity, polymorphism and 
scale-up. Different scale-up strategies include various crucial steps, for example, solvent and 
slurry crystallisation includes the critical steps of selecting appropriate solvent systems, 
determination of the thermo-dynamic region along with solid-liquid equilibrium of system, 
determination of kinetics of the system etc. Solvent based co-crystallisation methods suffer 
from the risk of change in kinetics of the system which result in crystallising the single 
component phase which acts as an impurity. And hence, solution crystallisation has issue of 
scale-up and purity. Moreover, the method requires large quantity of solvent. The further 
development of scalable co-crystallisation process is necessary which serve as a viable 
technique to prepare co-crystal as a marketed product. 
Solid state grinding and slow evaporation approaches are only best suited to small-scale 
operations. Moreover, both techniques possess scale-up limitations and may encompass 
batch-to-batch variations. Neat grinding gives yield of low purity and it requires high energy 
consumption.   
Co-crystallisation may result in rapidly dissolving co-crystals which demonstrate higher Cmax 
and decreased Tmax. For example, co-crystals of fluoxetine HCL: succinic acid (2:1) has 
shown a spring-parachute effect (See figure 2.4) which is considered as a limitation. During 
dissolution, the drug dissolves rapidly to achieve maximum concentration in a very short 
period of time. This process is termed as a spring effect. After rapid dissolution the API gets 
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transformed into the most stable form which is insoluble and results in decreased 
bioavailability. Spring parachute effect is described by figure 2.3. 
 
[Fig 2.3 Spring-parachute effect from Courtesy of Jules Remnar, Transfrorm Pharma] 
 
[Fig 2.4 Spring-parachute effect of fluoxetin HCl: succinic acid co-crystal from Courtesy of 
Jules Remnar, Transfrorm Pharma] 
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In early 2007, more than 4000 pet animals died because of renal failure caused by high 
consumption of pet-food containing melamine and cyanuric acid (Shan and Zavaorotko, 
2008). Both melamine and cyanuric acid are considered as safe drugs. But when they form a 
co-crystal which is highly insoluble in water, it leads to intra-tubular precipitation in kidney 
resulting in renal failure (Shan and Zavaorotko, 2008). This case study perhaps demonstrated 
for first time as to how co-crystals can alter physical properties in a negative manner and co-
crystallisation cannot be always beneficial.     
Pharmaceutical scientists have developed various co-crystallisation screening methods. But it 
was seen that solid state co-crystallisation offers enormous potential for green chemistry and 
also encompasses advantages over solvent based techniques due to factors such as  high 
yield, no or less use of solvent, low cost and sterioselectivity (Shan and Zaworotko, 2008). 
Shan and Zaworotko have also recommended solid based technique for preparation of co-
crystal (Shan and Zaworotko, 2008). 
Subsequently, pharmaceutical scientists are attracted towards solid-based continuous co-
crystallisation process. All of the conventional solid-based techniques mentioned above (for 
example, solid state grinding) are conducted in batch processes and thus encompass 
limitations of batch to batch variability. Therefore, it is a necessity to develop solvent assisted 
or solvent free – but continuous co-crystallisation techniques to prepare co-crystals and thus 
extrusion draws attention towards co-crystallisation. Hot melt extrusion has been successfully 
used previously for particle size reduction to enhance poorly water soluble drugs – those 
which are classified under BCS II (Ain et al., 2009). It is a single step process which has been 
successfully applied for preparation of solid dispersions (Ain et al., 2009).  
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Recently, our group has submitted a patent application for a solvent free continuous co-
crystallisation (SFCC) technique using melt extrusion (Paradkar et al, 2010), which has been 
successfully used for preparation of ibuprofen: nicotinamide co-crystals (Dhumal et al., 
2010). Continuous process encompasses advantages over batch processes in context of 
minimising process variations. It is a constant running process which is useful for large scale 
manufacturing in industries. It is time consuming and also gives repeatability of results.   
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2.3 Twin screw extrusion   
Twin screw extrusion is one of the comprehensively used processing techniques which have 
great application in plastic and polymer industry. Twin screw extrusion was not well known 
until mid-nineteenth century when it was first employed in polymer coating process for wire 
insulation. In 1940’s, extrusion process was first employed for bulk manufacturing of plastic. 
At present, extrusion process is not only employed for production of polymeric products but 
also more than half of all plastic products are manufactured using hot melt extrusion. 
Extrusion is a technique of processing drug and excipient by melting them under controlled 
conditions and followed by forcing them through the die to accomplish a desired shape. Such 
an extensively used processing technique for polymer production and compounding has been 
recently asserted as viable technique for pharmaceutical system. Consequently, extrusion 
technique has developed interest since abundant papers were published in pharmaceutical 
scientific literature over the last decade (Crowley et al., 2007). It has been reported that from 
early 1980’s the numbers of issued extrusion patents have been increasing steadily (Crowley 
et al., 2007). Being solvent free process, it encompasses benefits over solvent based 
techniques. Accompanying these benefits, continuous extrusion process provides possibility 
of single step high yield with desired formulation, withdrawing probability of batch to batch 
variation and thus proving to be economically beneficial. 
2.3.1 Introduction 
For pharmaceutical system, extrusion represents as an emerging and viable technique, since 
many research groups develop several pharmaceutical drug delivery systems such as 
granules, pellets (Follonier et al., 1994), sustained release tablets (Crowley et al., 2004) 
transmucosal and transdermal drug delivery system (Aitken-Nichol et al., 1996) and implants 
(Rothen-Wienhold., 2000) etc.  
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 [Fig 2.7 Percentage of patents issued from different countries since 1984 from Crowley et 
al., 2007] 
 Previously published scientific literature in pharmaceutical journals demonstrated that 
“continuous processing” acquires importance in the pharmaceutical industry. The extrusion 
process is an efficient method which offers several benefits over traditional approaches in 
context of simplicity, efficiency, continuous and solvent free processing. Furthermore, it 
eliminates the drying step and hence reduces processing time. Unlike solvent cast techniques, 
polymers can be easily shaped via heating into film. The imposed deep mixing and intense 
agitation causes de-aggregation which helps the drug to disperse uniformly in the molten 
polymer. It has been found that bioavailability of API improved in extruded dosage forms, 
since the drug gets dispersed at a molecular level. The twin screw extrusion was found to be 
an ideal technique in preparation of solid dispersions. The polymeric carrier and powder 
blend of API is transferred by a rotating screw in the presence of elevated temperature which 
results in the formation of a solid dispersion. Moreover in 1986, research by Gamlen revealed 
that extrusion is superior to other techniques because it involves low labour cost and less 
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capital investment (Gamlen., 1986).  Thus, extrusion serves as a surrogate for traditional 
processing approaches. 
2.3.2 Underlying mechanism of extrusion process 
As mentioned above, extrusion is a method which involves transfer of reacting components in 
the presence of elevated temperature via a rotating screw to prepare a product having desired 
shape by passing through a die (Crowley et al., 2007). 
 
      [Fig 2.8 Diagrammatic representation of an extruder from Crowley et al., 2007] 
The above figure 2.8 illustrates schematic diagram of a single screw extruder. Feed stock 
containing starting material is situated in the hopper to feed the material into the extrusion 
barrel by rotating screws. The extrusion barrel is a hollow part which accommodates a single 
or twin screw along with heating and cooling system in each zone for presetting the extrusion 
barrel at desired processing temperatures. As the feed stock starts passing along the length of 
the extrusion barrel under elevated temperature, it generates additional heat because of 
friction (Crowley et al., 2007). There are two types of frictions: first is the friction between 
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feeding material and internal barrel surface. Second is friction between material and screw 
interface which plays an important role in mixing or dispersing the reacting components. 
Resultant friction differences between screw interface and entire barrel is necessary for 
providing efficient forward flow in feeding passage (Crowley., 2003). It has been reported 
that the friction coefficient between starting components and internal barrel surface along 
with screw surface, affects the feeding efficiency (Crowley et al., 2007).  Furthermore, 
feeding efficiency also depends on bulk properties of material, for example, wherever the 
angle of the feed hopper is not more than angle of repose of material having poor flow 
property, it results in formation of a solid bridge at the throat of the hopper leading to an 
inconsistent flow (Crowley., 2003). Friction in the barrel can also be optimised by adjusting 
temperatures of the barrel zones. 
It has been mentioned that for maintaining elevated pressure in the compression zone and 
conveying zones, flow of material through the barrel must be efficient (Crowley., 2003). 
Changes in screw configuration can change the shear rate, melting process and mass flow of 
material. The melting step of components within the barrel is an imperative step because it 
leads to complete dispersion or mixing. If the material remains in a solid state inside the 
barrel, it might cause a blockage in the screw barrel and inside channels - those which assist 
the material in moving forward. 
The mechanical shear induced by dispersive zones or mixing zones under elevated 
temperature may cause degradation. Thus, establishment of processing conditions plays a 
vital role in optimisation of processing parameters which is dependent on the physico-
chemical properties of material – such as melting point of material, onset of degradation, 
stability of material at processing temperature etc.  
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2.3.4 Classification of Extruders 
The operating principles categorize extrusion technique into two classes namely ram 
extrusion and screw extrusion. Further classification was shown in fig. 2.10. 
                           
                                    [Fig 2.10 Classification of extruders] 
2.3.4.1 Ram Extrusion 
Accomplishment of positive displacement of material by pushing the component matrix 
through the die with high pressure generated by means of a piston is the operational principle 
of Ram extrusion. In this process, material gets softened when introduced into a cylinder 
under elevated temperature. Then this softened material is pressurised through the die with a 
Ram/Piston to achieve the desired shape. Limitation of this technique is that it has limited 
melting capacity which leads to temperature uniformity variation in extrudates. It has been 
mentioned that extrudates possesses poor homogeneity after Ram Extrusion.  
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2.3.4.2 Screw extrusion 
In screw extrusion, screw rotation inside a heated barrel provides shear and intense mixing of 
material. Screw extruders are equipped with three parts; conveying systems, die system and 
down-stream auxiliary equipment. Apart from these basic components, screw extrusion can 
be equipped with some additional systems like accurate feeders, PAT tools, pelletizers, 
thermocouples etc. The technique encompasses advantage of process control by monitoring 
zone temperatures, torque, pressure and screw-speed etc. Screw extrusion is further divided 
into single screw extruders and twin screw extruders.         
2.3.4.2.1 Single screw extrusion 
This is the most extensively used system in the world which is composed of one screw and is 
utilised for feeding, melting, devolatilizing and pumping (Crowley et al., 2007). Conveying, 
melting and pumping is achieved by frictional and viscous forces inside conveying zone and 
molten material is forced out through the die (see fig. 2.11). Depending on the manufacturing 
process, single screw extruders are further categorized into starve fed and flood fed. 
 
                 [Fig.2.11 Diagrammatic representation of single screw extruder]         
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In the flood fed method, screw speed determines output rate and the hopper rests on the feed 
throat for accepting materials while in the starve fed method, output is totally dependent on 
mass flow rate. However, single screw extruders have the limitation of being weak when it is 
reduced below the range of 18mm diameter. To overcome this drawback, a vertical screw is 
used which is driven from discharge end.  
Design of single screw extruder:- 
The design of extruder screws play an imperative role since implementation of particular 
arrangement of screw provides the required shear in the extrusion process. Whelan and 
Dunning described several applicable screw designs (Whelan and Dunning., 1988). It has 
been mentioned that single screw extruders are constructed with divisions in conveying, 
mixing, compressing and metering according to the required process.  
       
              [Fig.2.12 Design of a single extruder screw from Crowley et al., 2003] 
To prevent chemical reaction of reacting components with the screw as well as friction, 
surface coated stainless steel screws are used (Crowley et al., 2003). As mentioned above, 
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typically, screw division takes place in three different major zones according to their function 
as conveying (feeding), mixing (compression) and metering. The function of conveying zone 
is to feed the material from the hopper end to the mixing or compression zone. Thus, 
conveying screws are designed in a way that which they can provide wide channel depth to 
promote mass flow at constant rate (see fig. 2.12). Following the conveying zone, channel 
depth becomes narrower in the mixing or compression zone. The components convert into 
melt form in this zone and because of the narrow channel depth and mixing screws; the 
components get dispersed or start reacting with each other. The metering zone comes after 
the mixing zone which assists in positive mass transfer of extruded product. Similarly in the 
conveying section, mass flow in the metering zone relies upon the length of metering zone 
and channel depth. The product can then be shaped into its desired shape using a die. 
In the extrusion process, dimensions of screws are measured in terms of length/diameter 
(L/D) ratio. Screw dimensions vary in the range 25:1 to 40:1 according to the types of screw 
used. For a single screw extruder, it should be less than 36:1 while for twin screw extruder it 
can be up to 60:1. The flight gap between the outer diameter and barrel as well as 
intermeshing gap between two screws decide the channel depth. To achieve maximum output 
rate, free volume in the channel depth and torque should be at a desired equilibrium. Channel 
depth also affects torque; hence the design of the screw plays an imperative role in the 
extrusion process. 
2.3.4.2.2 Twin screw extrusion  
Twin screw extruders incorporate the interlocking of two screws inside an extrusion barrel as 
shown in the following figure 2.13. The first twin screw extruder was designed and 
developed in the late 1930’s in Italy. 
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                                       [Fig.2.13 Twin screw extruder screws] 
Screw configuration allows diversity in configuration and imposes different conditions like 
high shear, low shear, dispersive mixing etc. in the desired zones of screw. 
  
        A                                                                B              
 
                      [Fig.2.14 Counter-rotating screws (A) and co-rotating screws (B)] 
As shown in the above fig.2.14, twin screw extruders are divided into two designs namely co-
rotating and counter rotating, based on the type of rotation. Screws which rotate in the same 
direction are termed co-rotating and if they turn in opposite directions they are termed 
counter-rotating. Counter-rotating incorporates the principle of squeezing and thus is utilized 
for applying high shear forces. Since counter-rotating screws rotate in a crosswise direction to 
each other, there are chances of air entrapment. It also possesses the limitation of low-
maximum screw speed and as a result less output. On the other hand, rotation of co-rotating 
screw extruders has an intermeshing design which is exactly opposite to counter-rotating. 
They rotate in the same direction and hence are termed self-wiping (Breitenbach., 2002). 
Unlike counter-rotating screws, co-rotating screws are capable of operating at high speed, 
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accompanying good mixing and conveying which gives high output. In this way, co-rotating 
screws offer several advantages over counter-rotating screws and consequently possess great 
industrial applicability. 
2.3.5 Advantages of twin screw extrusion over single screw extrusion 
1) Simplicity of material feeding. 
2) High dispersing Capacity: - Due to typical screw arrangements, twin screw provide 
high kneading and dispersing capacities. 
3) Short transit time: - Self-wiping screws ensure high speed which results in short 
transit time and emptying the barrel. This tendency protects material from being over-
heated inside the screw barrel. 
4) Versatility: - Optimization of screw configuration can be easily achieved by means of 
altering arrangements of screw elements and thus the process can be modified 
according to application of high or low shear.  
Both co-rotating and counter-rotating screws are further classified into non-intermeshing and 
fully intermeshing. The non-intermeshing design is utilised largely to withdraw volatiles as 
well as in processing of highly viscous materials. On the other hand, self wiping fully 
intermeshing screws minimize the chances of overheating the material. The fully 
intermeshing screw operation takes place on the principle of first in/first out. Unlike non-
intermeshing screws, fully intermeshing screws are susceptible to high torque. 
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2.3.6 Twin screw extrusion in co-crystallisation 
Twin screw extrusion offers close packing of material along with efficient mixing of the 
starting crystalline components. Intense agitation in twin screw extrusion leads to an increase 
in surface contact of the components that initiates co-crystallisation without using any solvent 
(Medina et al., 2010).   
 
      [Fig. 2.15 Formation of co-crystals by twin screw extrusion] 
Hot melt extrusion technology has been successfully developed and submitted a patent 
application for a continuous co-crystallisation process by University of Bradford (Paradkar et 
al., 2010). Paradkar et al in 2010, successfully demonstrated preparation of many co-crystals 
by solvent free continuous co-crystallisation (SFCC) such as ibuprofen: nicotinamide (1:1), 
carbamazepine: saccharin (1:1), carbamazepine: nicotinamide (1:1), caffeine: malic acid (1:1, 
2:1), theophylline: malic acid (1:1) etc. Dhumal et al in 2010 successfully prepared 
ibuprofen: nicotinamide (1:1) co-crystals in the form of agglomerates by hot melt extrusion 
(Dhumal et al., 2010). They have demonstrated the potential of the HME technique for co-
crystallisation along with agglomeration in one step (see fig.2.15).  
API Co-former 
Co-crystals 
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Recently, Medina et al. in 2010 have demonstrated successful preparation of caffeine: oxalic 
acid (2:1) and AMG 517: sorbic acid (1:1) co-crystals by twin screw extrusion (TSE). They 
have mentioned that in twin screw extrusion, combination of optimum parameters (e.g. screw 
speed, temperature, residence time etc.) is mandatory to achieve pure co-crystals (Medina et 
al., 2010).   
The cited literature suggests that extrusion is a promising technology for co-crystallisation. 
Furthermore, it offers advantages over traditional approaches in respect to solvent free and 
continuous process and hence, twin screw extrusion is also accepted by several 
pharmaceutical companies. It has been proven that a combination of shear deformation and 
controlled heat gives rise to co-crystallisation and hence there is a further need to understand 
the processing in respect to study of the effect of different process variables.  
Considering all the above issues, a co-crystallisation study was decided to be carried out by 
twin screw extrusion. 
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__________________________________________________________________________________ 
         Chapter 3: Materials and methods 
  =======================================================================  
3.1 Materials 
Specifications of materials used are described in following table no. 3.1. 
No. Drug/ Chemical/ 
Solvent 
Supplier Grade Lot Number 
1. Carbamazepine  Taj Pharmaceuticals, 
India 
Analytical Grade TPL/CARB/002 
2. Saccharin Aldrich, UK Analytical Grade S46968-108 
3. Ethanol Fisher chemicals, UK HPLC Grade 1161703 
4. Methanol Fisher chemicals, UK HPLC Grade 1163434 
5. Toluene  Sigma-Aldrich, UK HPLC Grade SHBB3387 V 
6. Sodium dodecyl 
sulphate 
VWR international 
Ltd., UK 
Analytical Grade 10 G 220003 
7. Butanol Alfa Acer, UK Analytical Grade J04w014 
8. Octane Aldrich, UK Analytical Grade S26799-335 
9. Buffer  BDH Anal R, UK Analytical Grade A756825 
10. o-phosphoric acid BDH Anal R, UK Analytical Grade 5870370 B 
11. Deuterated 
Acetone  
Cambridge Isotope 
Laboratories, UK 
Analytical Grade PSO11G-108 
12. Sodium chloride Sigma-Aldrich, UK Analytical Grade BCBF1708 V 
13. Hydrochloric acid Fisher Chemical, UK Analytical Grade 
(36%) 
1017208 
14. Triton X-100 Alfa-Acer, UK Analytical Grade 10162155 
15. Potassium 
bromide 
Sigma-Aldrich, UK  Analytical Grade S44777-308 
                                 [Table. 3.1 specifications of chemicals] 
3.2 Methods 
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Following are the techniques for physico-chemical characterisation of starting crystalline 
components and prepared co-crystals.  
3.2.1 Vibrational spectroscopy 
3.2.1.1 Infra-red (IR) spectroscopy  
The samples were prepared by using a KBr disc method. The weight ratio of drug to KBr in 
disc was maintained at 9:100. The discs were analysed at room temperature using a Digilab 
FTS 2000 spectrometer (Randolph, USA) equipped with deuterated triglycine sulphate 
(DTGS) detector. Spectra were recorded between 4000 to 600 cm-1 at resolution rate 4 cm-1, 
by measuring and taking average of 128 scans for each samples. 
3.2.1.2 Raman spectroscopy 
Raman spectra were recorded using a Renishaw (UK) Raman microscope analyser equipped 
with a diode laser which emits light of wavelength 785nm. Maximum output of the diode 
laser was 50mV at source point and approximately 20mV at sample. A 50X objective was 
used to emit a light beam of diameter 52μ. At 4 cm-1 spectral resolution, 9 scans were 
collected at wave number range 100-3500 cm-1. A charged coupled device detector was used 
to collect data. 
3.2.2 Thermal analysis 
3.2.2.1 Thermo-gravimetric analysis (TGA) 
Determination of onset of degradation was achieved using a TA Instruments Q 5000 Thermo 
Gravimetric Analyser (Crawley, UK), equipped with a RSC90 cooling unit. Each pan was 
tared to store the weight of the pan as an offset before loading samples. Approximately, 2-4 
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mg of sample was loaded into an aluminium pan and heated at a rate of 10⁰C/min along with 
nitrogen at a flow rate of 50mL/min to maintain an inert environment. 
3.2.2.2 Differential scanning calorimetry (DSC) 
DSC thermograms were obtained by using a TA Instruments Q2000 differential scanning 
calorimeter (Crawley, UK) equipped with an RSC90 cooling unit to analyze and comprehend 
heat flow in the starting crystalline components as well as the resulting crystalline products. 
The instrument was calibrated using standard indium metal. An empty pan was used as 
reference. Approximately 2-4 mg of each sample was loaded into the aluminium pan. 
Temperature range for all samples was selected within 25⁰-200⁰C. A heating rate of 10○C/ 
min was used and the nitrogen flow rate was 50mL/min to maintain inert environment. 
3.2.3 X-ray diffractometry 
X-ray diffractogram of the starting crystalline components and resultant crystalline products 
prepared by solvent crystallization and hot melt extrusion methods were assessed using 
Bruker D8 diffractometer (Coventry, UK), having X-ray wavelength 0.154 nm and a 40 KV 
Cu source with filament emission 40 mA. All samples were scanned from 2 to 30° (2θ) using,  
a 0.01° step width and  1 s time count, while the scatter slit and receiving slit were 0.2○ and 
1○, respectively. 
3.2.4 Density determination 
True density of pure carbamazepine, pure saccharin, and co-crystal (prepared by solvent 
crystallization) was calculated using a Micromeritics AccuPyc 1330 Helium pycnometer 
(USA). An empty cup of volume 10 cm3 was analysed initially to check how close the value 
of average volume is to zero and the error was found to be less than 0.05%. The instrument 
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was calibrated by using dense metal balls of a calibration standard having a known volume of 
6.372882 cm3. Helium gas of percent purity more than 99.995% was passed at a pressure of 
20 psig with equilibration rate 0.005 psig/min at temperature of 25⁰C+2⁰. Following 
calibration, the samples of known mass were added to the cup to analyse the sample in triplet 
and an average density was calculated.  
3.2.5 Ultra-violet visible (UV-vis) spectrophotometry 
U.V. absorption spectra of carbamazepine and saccharin were achieved using Cary 50 Varian 
probe UV-visible spectrophotometer (Australia). Samples were prepared in methanolic 
solution. UV cell made up of quartz having path length 1cm was used for experiment. Spectra 
were recorded by taking average of 50 scans for each sample within the range 200 to 500 nm. 
Cary WinUV scan application version 02.00(25) software was used to achieve spectrum.   
3.2.6 High performance liquid chromatographic (HPLC) method development 
3.2.6.1 Nano-emulsion liquid chromatography (NELC)  
Simultaneous estimation of carbamazepine and saccharin was accomplished by using X-
Bridge BEM 300 C18 column (Waters, UK) having internal diameter 4.6mm and column 
length 250mm bearing particle size 3.5μm, kept at room temperature. The composition of the 
nanoemulsion mobile phase was SDS 1.5%, octane 0.7%, butanol 3%, and 94.8% phosphate 
buffer (10mM) adjusted to pH 3. The system was sonicated and degassed for 15 min to 
achieve clarity and used after filtration through a 0.45μm filter. An HPLC system equipped 
with a Hewlett-Packard (HP) 1050 pump along with auto sampler coupled with on-line 
membrane degasser and the system was associated with a U.V. detector at an excitation 
wavelength 213 nm. Determination of iso-absorption point of carbamazepine and saccharin 
was achieved by using Ultra-violet visible (UV-vis) spectrophotometer as mentioned in 
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method (section 3.2.5). Flow rate of mobile phase and injection volume were 1mL/min and 
30μL, respectively. 
3.2.6.2 Development of optimum mobile phase 
Surfactant and co-surfactant (Selection and study of concentration effect on retention time of 
compounds):- 
Sodium dodecyl sulphate (SDS) was used which is an anionic surfactant. Cationic surfactant 
was not useful in this case because, it affects the retention time of polar analytes (Li and 
Wang, 1999). In case of co-surfactants, the tendency of adsorption is increases, as alcohol 
chain-length increases and thus 1-butanol having medium-chain alcohol has been selected. 
Effect of SDS and 1-butanol concentration on retention time of compounds was studied in a 
range of 0.5-2.5% (w/w) and 1-5% (w/w), respectively, to select optimum concentration of 
SDS and 1-butanol.  
Oil phase (Selection and study of concentration effect on retention time of compounds):- 
In o/w nano-emulsion, if length of oil chain is increased then solubility of oil in water gets 
decreased (Li and Wang, 1999). Considering the fact, octane was selected as it possesses 
short chain length. Effect of oil concentration on retention time of compounds was studied in 
range of 0.3-0.9% (w/w) to select optimum concentration of octane. 
Selection of molar concentration of phosphate buffer (water phase):- 
To select optimum molar concentration of phosphate buffer, effect of different molar 
concentrations on retention time of compounds was studied in a range of 5mM- 25mM. 
Selection of pH of mobile phase:- 
Study of pH effect on retention time of analytes was examined at a range of pH 1 to 5. 
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3.2.6.3 Preparation of mobile phase 
Mobile phase was composed of SDS- octane- butanol- phosphate buffer (1.5: 0.7: 3: 97.5, 
w/w/w/w). The molar concentration of phosphate buffer used was 10mM. Mobile phase was 
prepared by adding SDS into phosphate buffer under stirred conditions, followed by drop 
wise addition of octane and then butanol. The mobile phase was adjusted at pH 3 using o-
phosphoric acid. To achieve homogenous emulsion, mobile phase was sonicated for 10 min 
and filtered through 0.35μm nylon filter paper (Gelman Science, Germany). Prior use in 
HPLC system, the mobile phase was degassed using ultrasonic bath under vacuum.   
3.2.6.4 Globule size determination 
Average globule size of nano-emulsion was measured using a Malvern Nano-S ZEN 3600 
Zetasizer (Worcestershire, UK). A low volume disposable sizing cuvette was cleaned with 
filtered dispersant (deionised water) having RI 1.330 and used for measurement of globules 
in nano-emulsion. The sample was loaded into the cuvette slowly and carefully to avoid air 
bubbles with the help of injection syringe filters. Ultrasonication was done for few minutes to 
remove any tiny bubbles if present. The cuvette was loaded into the cell holder and the 
sample was scanned at a count rate of 76.6 kcps from measurement position 4.65mm for 60 
seconds under 25⁰C temperature. 
3.2.6.5 Preparation of standard stock solution 
Carbamazepine and saccharin (10 mg each) were weighed accurately and transferred to 100 
ml volumetric flask. They were dissolved in 40 ml of methanol and were further diluted with 
water to obtain the final concentration 100 μg/mL of carbamazepine and saccharin, 
respectively. 
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3.2.6.6 Preparation of calibration standard solutions 
Calibration standard solutions were prepared by diluting standard stock solution, in range of 
2- 100μg/mL. All samples were sonicated followed by filtration through 0.35μm injection 
filter. 
3.2.6.7 Validation of method 
Validation of developed method was performed in terms of linearity, precision, recovery, 
accuracy, limit of detection and quantification using International conference on 
harmonization (ICH) guidelines. 
Selection of analytical concentration range (Calibration, linearity and range):- 
Using standard stock solution, eight dilutions were made which contains 2, 5, 10, 15, 20, 25, 
35 and 50μg/mL of carbamazepine and saccharin in each. All samples were sonicated 
followed by filtration through 0.35μm injection filter. Linearity was determined by assessing 
eight samples in sixlet.  
Precision:- 
Intra-day precision (Repeatability):- 
Intra-day precision was analysed by injecting nine different concentrations which contain 
carbamazepine and saccharin in a concentration range of 2, 5, 10, 15, 20, 40, 60, 80 and 
100μg/mL.  All samples were sonicated followed by filtration through 0.35μm injection 
filter. Samples were analysed by repeating each samples five times (n=5) and standard 
deviation is calculated. 
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Inter-day precision (Reproducibility):- 
Inter-day precision was analysed by injecting five different concentrations which contain 
carbamazepine and saccharin in a concentration range of 5, 10, 20, 40 and 80μg/mL.  All 
samples were sonicated followed by filtration through 0.35μm injection filter. Samples were 
analysed by repeating each samples three times (n=3) and standard deviation is calculated. 
Recovery:- 
Recovery of carbamazepine and saccharin was calculated by preparing samples of known 
concentrations in three different concentration ranges viz; 80%, 100%, 120%. Each sample 
was injected in triplet (n=3) and variation was examined by calculating relative standard 
deviation (%RSD). 
Accuracy:- 
Accuracy of the method was determined by analysing three different concentration ranges of 
carbamazepine and saccharin namely low (5μg/mL), medium (20μg/mL) and high 
(50μg/mL). Accuracy was examined by evaluating comparison between true concentration 
and observed/calculated spike concentration.  
Analysis of carbamazepine: saccharin (1:1) co-crystal:- 
Carbamazepine: saccharin co-crystals (10mg) prepared by solvent crystallisation were 
dissolved in 4mL of methanol and further diluted with distil water up to 100mL to make 
concentration of 92.70μg/mL and 7.30μg/mL for carbamazepine and saccharin, respectively. 
The samples were filtered by 0.35μ filter. The sample analysis was carried out in sixlet and 
relative standard deviation was calculated. 
3.2.7 Co-crystal preparation methods 
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Following are the two methods which are used for preparation of carbamazepine: saccharin 
(1:1) co-crystals. 
3.2.7.1 Solvent crystallisation 
As carbamazepine: saccharin (1:1) co-crystals are not commercially available, solvent 
crystallization technique which is previously reported by Hickey et al was used to prepare 
pure co-crystals (Hickey et al., 2007). Co-crystallisation was performed in a 500mL conical 
flask. The temperature of the reaction vessel was maintained at 70⁰ C by circulating water. 
Anhydrous carbamazepine - 21g (0.089 mol) and saccharine 16.3g (0.089 mol) were 
dissolved in a mixture of ethanol (62.5%) and methanol (37.5%). The mixture was then 
allowed to heat for 1 hour at 70⁰C along with continuous stirring. Temperature was decreased 
by 10⁰C every 25 min until the solution temperature reached 30? C. After a few minutes, 
stirring was stopped and co-crystals were isolated, washed with cold ethanol and stored in an 
air tight container. The determined recovery was approximately 15g. Prepared pure co-
crystals have been used as a standard. 
3.2.7.2 Twin screw extrusion 
Carbamazepine [21.0g (0.089 mol)] and saccharin [16.3g (0.089 mol)] in 1:1 molar ratio 
were mixed together to prepare a physical mixture. During preparation of physical mixture, 
anhydrous carbamazepine picks up the moisture from atmosphere and undergoes moisture 
induced phase transformation to form carbamazepine dihydrate. Hence, before experiment, 
XRD was carried out to confirm the absence of carbamazepine dihydrate in physical mixture. 
Using a 16mm co-rotating twin-screw extruder (Pharma lab, Thermo scientific, UK) co-
crystallisation was carried out. Screw length to diameter ratio was 40:1 and different screw 
configurations were used as mentioned below. The extruder was operated without a die. The 
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physical mixture was added into the extruder with the aid of a gravimetric feeder. The 
physical mixture was feeded at a rate 2g/min in presence of extruder screw speed 20rpm, for 
all experiments (minimum loading of extruder is 20g). Observed torque (%) was recorded 
and the residence time (min) of powder was calculated. The twin screw extruder used for this 
study was shown in figure 2.9.  
3.2.7.2.1 Screw elements/mixing paddles 
There are various screw elements which can be used for arrangement of screw configuration 
to achieve the desired compression and decompression, forward conveying, dispersive and 
staggered mixing as well as discharge of final product from the extrusion barrel. The 
following figure 3.1 demonstrates different mixing paddles and their arrangement in screw 
configurations during twin screw extrusion process. 
 
                         [Fig.3.1 Different angles created by mixing paddles] 
As shown in the following figure 3.1, conveying screw elements are applicable only for 
pushing the physical mixture in a forward direction. They provide limited mixing. However, 
mixing paddles offer high mixing and less conveying. The intensity of mixing is depending 
upon the angle of screw elements. A small angle provides a high compression and less 
mixing while wide angle provides high mixing and low compression.  
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The following table and figure 3.2 demonstrate the applicability of different screw 
arrangement for achieving desired effect. 
 
                        [Fig. 3.2 Application of various types of screws] 
 
                 [Table. 3.2 Screw arrangements and their special effects] 
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3.2.7.2.2 Reverse elements 
Reverse elements provide material flow opposite to the direction of conveying elements. 
Reverse elements helps to provide high shear by increasing the residence time of binary 
mixture in mixing zone which results in improvement in product quality (Chandrasekaran and 
Karve., 1997).  
3.2.7.2.3 Screw configurations and geometry 
The following are different Screw configurations adopted and studied during process of 
achieving continuous co-crystallisation. The following table 3.3 describes the various 
configurations used in this study and their corresponding shear intensities. 
No. Screw configuration Shear intensity 
1. Configuration- I WRE* Very high shear (torque >50%) 
2. Configuration- II WRE High shear (torque = 20-45%) 
3. Configuration- III WRE Moderate shear (torque = 5-20%) 
4. 
Configuration- IV 
RE* 
Moderate shear 
WRE 
5. 
Configuration- V 
RE 
Moderate shear 
WRE 
       
              [Table 3.3 Screw configurations and their respective shear intensities] 
*RE = Reverse elements  
*WRE = without reverse elements 
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The following are screw geometries shown in the above five configurations:- 
Configuration I: Very high shear.  
Length 
(cm) 
Element type 
Diagram 
19 Forward conveying 
 
1 30forward mixing 
1 60forward mixing 
1 90 mixing 
2 Forward conveying 
1 0 mixing 
1 Forward conveying 
1 0 mixing 
2 Forward conveying 
1 0 mixing 
2 90 mixing 
0.5 Forwarding 
6 Forwarding 
1.5 Discharge 
 
                                  [Table: 3.4 Screw configuration I] 
Description of configuration I:-  
Configuration I contain four mixing zones separated by lower numbers of conveying screws. 
It includes a large number of 0⁰ mixing elements which provide very high shear deformation 
to the material (see table 3.4). 
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Configuration II:-  
Length (cm) Element type Diagram 
19 Forward conveying 
 
1 30forward mixing 
1 60forward mixing 
1 90 mixing 
2 Forward conveying 
0.5 0 mixing 
1 Forward conveying 
0.5 0 mixing 
2 Forward conveying 
0.5 0 mixing 
1 Forward conveying 
0.5 0 mixing 
2 90 mixing 
6.5 Forward conveying 
1.5 Discharge 
                                         [Table.3.5 Screw configuration II] 
Description of configuration II:- 
Configuration II possesses the same number of 90⁰ screws elements as that of configuration I 
which provides dispersive mixing. Compared to configuration I, it contains short length 
mixing zones containing 0⁰ screw elements and the total number of 0⁰ screw elements is also 
less. Hence, configuration II (high shear) provides lower shear intensity compared to 
Configuration I (very high) (see table 3.5). 
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Configuration III:- 
Length (cm) Element type Diagram 
22 Forward conveying 
 
0.5 90forward mixing 
0.5 60forward mixing 
0.5 30 mixing 
3 Forward conveying 
0.5 90 mixing 
0.5 60Forward conveying 
0.5 30 mixing 
3 Forward conveying 
0.5 90 mixing 
0.5 60Forward conveying 
0.5 30 mixing 
6 Forward conveying 
1.5 Discharge 
                                   [Table. 3.6 Screw configuration III] 
 
Description of configuration III:- 
Configuration III encompasses three identical mixing zones separated by three conveying 
elements. Each mixing zone includes couple of 90⁰, 60⁰ and 30⁰ screw elements in a 
direction from hopper to discharge screw. Because of 30⁰ and 60⁰ screw elements, 
configuration III provides moderate shear to the material (see table 3.6).                                 
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Configuration IV:- 
Length (cm) Element type Diagram 
22 Forward conveying 
0.5 60forward mixing 
0.5 60forward mixing 
0.5 90 mixing 
3 Forward conveying 
0.5 60forward mixing 
0.5 60forward mixing 
0.5 90 mixing 
3 Forward conveying 
0.5 60forward mixing 
0.5 60forward mixing 
0.5 90 mixing 
6 Forward conveying 
1.5 Discharge 
                                           [Table 3.7 Screw configuration IV] 
Description of configuration IV:- 
Screw configuration IV was made by altering the sequence of screw elements in a mixing 
zone of configuration III. In configuration IV, screw elements in each mixing zone were 
arranged in the order 60⁰, 60⁰ and 90⁰ in a direction from the hopper to discharge end. The 
number of mixing zones were kept constant as per configuration III. Configuration IV 
encompasses three identical mixing zones separated by three conveying elements. 
Configuration IV also provides medium shear to the material in the mixing zone (see table 
3.7).  
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Configuration V:-  
Length (cm) Element type Diagram 
22 Forward conveying 
 
0.5 30forward mixing 
0.5 60forward mixing 
0.5 90 mixing 
3 Forward conveying 
0.5 30forward mixing 
0.5 60forward mixing 
0.5 90 mixing 
3 Forward conveying 
0.5 30forward mixing 
0.5 60forward mixing 
0.5 90 mixing 
6 Forward conveying 
1.5 Discharge 
                                        [Table 3.8 Screw configuration V]                                
Description of configuration V:-   
This configuration involves identical number of zones as per configuration III and IV. Screw 
elements in each mixing zone were arranged in reverse order as that of configuration III. This 
configuration provides medium shear (see table 3.8).  
3.2.7.2.4 Temperature profiles 
In this project, co-crystallisation experiments via twin screw extrusion were carried out at an 
elevated temperature using six different temperature profiles. During selection of optimum 
processing temperature, co-crystallisation experiments were carried out at two temperature 
profile namely T-150⁰C and T-145⁰C (Table 3.9 and 3.10). The extrusion batches were 
carried out mostly by using temperature profiles T-140⁰ and T-130⁰ which are represented by 
following table 3.11 and 3.12. The extrusion barrel is divided into nine different temperature 
zones. The highest temperature was maintained in zone seven as it encompasses mixing 
region in it (see fig. 3.3).  
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                                    [Fig.3.3 Different zones of extrusion barrel]  
As mentioned above, in the process of selecting optimum process temperature for co-
crystallisation via extrusion, process were carried out using following two temperature 
profiles T-150⁰C (Table 3.9) and T-145⁰C (Table 3.10). 
Different Zones 
in Extruder 
Barrel 
Zone 
10 
Zone 
9 
Zone 
8 
Zone 
7 
Zone  
6 
Zone 
5 
Zone 
4 
Zone 
3 
Zone 
2 
Temperature  
of zones 
 
70 
 
100 
 
130 
 
150 
 
130 
 
110 
 
75 
 
50 
 
25 
      [Table 3.9 Diagrammatic representation of temperature profile T-150⁰C] 
Different Zones 
in Extruder 
Barrel 
Zone 
10 
Zone 
9 
Zone 
8 
Zone 
7 
Zone  
6 
Zone 
5 
Zone 
4 
Zone 
3 
Zone 
2 
Temperature  
of zones 
 
70 
 
100 
 
130 
 
145 
 
130 
 
110 
 
75 
 
50 
 
25 
        [Table 3.10 Diagrammatic representation of temperature profile T-145⁰C] 
Following are the two temperature profiles (T-140⁰C and T-130⁰C) which are selected and 
used as an optimum profiles for co-crystallisation 
Different Zones 
in Extruder 
Barrel 
Zone 
10 
Zone 
9 
Zone 
8 
Zone 
7 
Zone  
6 
Zone 
5 
Zone 
4 
Zone 
3 
Zone 
2 
Temperature  
of zones 
 
70 
 
100 
 
130 
 
140 
 
130 
 
110 
 
75 
 
50 
 
25 
     [Table 3.11 Diagrammatic representation of temperature profile T-140⁰C] 
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Different Zones 
in Extruder Barrel 
Zone 
10 
Zone 
9 
Zone 
8 
Zone 
7 
Zone  
6 
Zone 
5 
Zone 
4 
Zone 
3 
Zone 
2 
Temperature  
of zones 
 
120 
 
120 
 
 
120 
 
130 
 
120 
 
100 
 
75 
 
50 
 
25 
      [Table 3.12 Diagrammatic representation of temperature profile T-130⁰C] 
The temperature profile shown below (Table 3.13) was used only for one particular 
experiment. A minor alteration was made to temperature profile T-140⁰, by increasing 
temperature of heating zone 6 and 8 by 10⁰C, so that three consecutive heating zones 
provided high temperature to the physical mixture. 
Different 
Zones in 
Extruder 
Barrel 
Zone 
10 
Zone 
9 
Zone 
8 
Zone 
7 
Zone 
6 
Zone 
5 
Zone 
4 
Zone 
3 
Zone 
2 
Temperature 
of zones 
 
110 
 
120 
 
140 
 
140 
 
140 
 
110 
 
75 
 
50 
 
25 
                  [Table 3.13 Alteration in Temperature profile T-140⁰] 
The temperature profile shown below (table 3.14) was also used only for one particular 
experiment. The extrusion process was carried out at room temperature of 16⁰C. 
Different 
Zones in 
Extruder 
Barrel 
Zone 
10 
Zone 
9 
Zone 
8 
Zone 
7 
Zone 
6 
Zone 
5 
Zone 
4 
Zone 
3 
Zone 
2 
Temperature 
of zones 
 
16 
 
16 
 
16 
 
16 
 
16 
 
16 
 
16 
 
16 
 
16 
                   [Table 3.14 Temperature profile set at room temperature] 
3.2.7.2.5 Effect of process variables 
To study the effect of process variables, the following changes were made to the co-
crystallisation process. 
- Screw speed 
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As mentioned above (in method 3.2.7.2), in process of co-crystallisation via twin 
screw extrusion, most experiments were carried out at screw speed 20 rpm. A 
reduction in the screw speed by 50% (10 rpm) was made to check whether screw 
speed considerably affects the process of co-crystallisation or not.  
- Particle size  
Micronisation of carbamazepine and saccharin was achieved using an FPS Labo mill 
jet mill micronizer (Italy) (see fig.3.4). A sample of weight 10g was loaded with a 
feed pressure of 5.5 bars and grind pressure of 6 bars. The sample was allowed to 
micronise for 5 min and collected in a collection chamber. 
 
     [Fig.3.4 FPS Labo mill jet mill micronizer] 
     After micronisation, carbamazepine and saccharin were divided into two parts 
according to particle size- fine (< 250μ) and coarse (>250μ). The separation was 
achieved by sieving using sieve of particle size 250μ.  
Carbamazepine and saccharin possessing identical particle size were mixed in a 1:1 
molar ratio to prepare a physical mixture and the co-crystallisation process was 
carried out using twin screw extrusion to check whether particle size of starting 
crystalline components affected co-crystallisation process or not.   
 Development of a solvent free continuous co-crystallisation technique for carbamazepine-saccharin         Page | 59  
- Addition of organic solvents 
Effect and choice of solvent addition on co-crystallisation was studied by small 
additions of polar and non-polar solvents into the physical mixture. Methanol was 
selected as a polar while, toluene as a non-polar solvent. Both were added (drop 
wise) separately in 5% (w/w) in physical mixture before processing, to study the 
reaction kinetics of co-crystallisation and results were compared. Anhydrous 
carbamazepine picks up moisture from atmosphere and undergoes moisture induced 
phase transformation to form the most stable carbamazepine dihydrate form during 
addition of methanol. Hence, XRD of physical mixture was carried out to confirm 
the absence of carbamazepine dihydrate in physical mixture. 
- Addition of water in binary mixture and using carbamazepine dihydrate as a starting 
crystalline component 
Carbamazepine dihydrate (CBZ: 2H2O) contains 13.2% of water in its crystal lattice 
(McMahan et al., 1996). To verify differences in the co-crystallisation process as well 
as in the purity of the prepared co-crystals, the process was carried out in two ways; 
firstly by 5% (w/w) water addition to the physical mixture and secondly; by using 
carbamazepine dihydrate as a starting component along with saccharin in the physical 
mixture. Carbamazepine dihydrate was prepared by the previously reported method 
mentioned by McMahan et al (McMahan et al., 1996). P-monoclinic form of 
carbamazepine was stirred in water in 1:4 w/v proportions for 24 hours and 
carbamazepine dihydrate was filtered and dried at room temperature. The 
carbamazepine dihydrate was characterised by X-ray diffractometry and differential 
scanning calorimetry. 
- Reverse elements  
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Reverse elements were used in the extruder screw configuration to increase the 
residence time of the physical mixture inside the extrusion barrel at elevated 
temperature and moderate shear. 
3.2.8 Characterisation of co-crystals 
Co-crystals produced by a solvent crystallisation and twin screw extrusion methodology were 
characterised using IR spectroscopy, Raman spectroscopy, TGA, DSC, x-ray diffractometry 
and density determination (as mentioned above).   
3.2.8.1 Dissolution 
Dissolution studies were carried out using USP type II dissolution test apparatus. For 
dissolution studies, simulated gastric fluid (SGF) having a pH-2 was used as a dissolution 
medium and 200mg of co-crystals in the form of agglomerates were loaded into the 
dissolution vessel containing 900mL SGF maintained at 37+0.5⁰C and stirred at 100 rpm.  
Samples were collected after specific intervals and replaced with fresh dissolution medium. 
Collected samples were filtered using 0.35μm syringe filter and diluted two times. Samples 
were studied in triplicate and coefficient of variation was calculated. The obtained data was 
analysed using PCP-Disso software V3 (Poona College of Pharmacy, Poona, India). 
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__________________________________________________________________________________ 
         Chapter 4: Results and discussion 
=======================================================================  
4.1 Work-flow of results and discussion 
This chapter is divided in three main parts namely; physico-chemical characterisation, 
development of analytical method and co-crystallisation assessment by twin screw extrusion. 
The first part covers result and discussion of physico-chemical characterisation of pure 
starting crystalline components (carbamazepine and saccharin) along with prepared pure co-
crystals obtained by solvent crystallisation using the characterisation techniques described in 
chapter 3 (section 3.2). Analytical method development involves optimisation and validation 
of high performance liquid chromatography (HPLC) for simultaneous estimation of co-
crystal components. Co-crystallisation assessment by twin screw extrusion is a final part of 
the results and discussion. This covers process optimisation and studies of the effect of 
different process variables on co-crystallisation via the extrusion technique. Pharmaceutical 
performance of extrusion derived co-crystals (using different process variables) was 
examined by in-vitro dissolution test and drug release is compared to those from pure 
carbamazepine and pure co-crystal prepared by solvent crystallization.  
4.2 Physico-chemical characterisation 
As a part of preliminary studies, physico-chemical characterisation of carbamazepine, 
saccharin and prepared co-crystal prepared by solvent crystallization was carried out using 
techniques mentioned in section of methods (3.2). 
4.2.1 Physicochemical characterisation of pure carbamazepine 
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4.2.1.1 Vibrational spectroscopy 
4.2.1.1.1 IR spectroscopy 
Structural determination and confirmation of API is an important part of raw material 
analysis. The infrared absorption spectrum of carbamazepine was obtained using an infrared 
spectrophotometer. Characteristic absorption bands (Fig. 4.1) and a description of 
characteristic infrared bands is given below. 
In a carbamazepine molecule, the carboxamide group consists of one carbonyl group (-C=O) 
and one amide group (-NH2). The carboxamide group is responsible for formation of 
homodimer because the carbonyl group acts as a hydrogen bond acceptor and the amide 
group acts as a hydrogen bond donor. syn-NH in the amide group acts as a hydrogen bond 
donor and anti-NH is involved in formation of carbamazepine dihydrate and other solvates 
such as DMSO, acetone etc (see fig. 4.2). 
                  [Fig.4.1 FTIR spectra of anhydrous carbamazepine (form III)] 
Free anti -NH
3464.145
Hydrogen bonded
syn -NH 
3159.651
(-C=O) carbonyl 
group strech
1676.137

 Development of a solvent free continuous co-crystallisation technique for carbamazepine-saccharin         Page | 64  
                                      [Fig.4.3 Raman spectrum of carbamazepine]  
Characteristic Peak                        Description of vibrational mode  
1623.32 Non-aromatic [C=C] stretch 
1599.25 Secondary amide [N-H] bend 
1563.870 [C=C] aromatic stretching 
1489.24 [C=C] symmetric stretching, aromatic [C-N] stretch of tertiary 
amide 
1412.21 [C=C] stretch, [C-H] bend 
1308.58 Non-aromatic C-H in place bending 
1250.32 [C-N] stretch amide III 1⁰ amide 
1222.52 Amide III [C-N] stretch 
1041.85 Aromatic [C-H] in lane bending 
1024.045 Aromatic [C-H] in plane bending 
723.26 Tertiary amide [C-N-C] stretch 
168.27 Torsion 
124.09 Lattice vibration 
             [Table 4.1 Different types of vibrational modes in carbamazepine] 
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4.2.1.2.2 Differential scanning calorimetry 
To determine the melting range of p-monoclinic form of carbamazepine, thermal screening 
was accomplished by using differential scanning calorimetry. 
 
 
 
 
 
 
 
                                      
[Fig.4.5 DSC thermogram of p-monoclinic form of carbamazepine] 
It has been previously reported that the p-monoclinic form of carbamazepine melts at 
174.8⁰C (Grzesiak et al., 2003). The above DSC thermogram of carbamazepine (see fig.4.5) 
showed an onset of melting at 174.19⁰C and exhibited single endothermic peak at 175.57⁰C. 
It has been observed that 28.21J/g of normalised energy was utilized for melting of the p-
monoclinic form. Following single exothermic peak at 175.57⁰C, recrystallization at 176.66 
⁰C has been observed which confirms that the p-monoclinic form III gets recrystallised into 
the triclinic form-I of carbamazepine which shows melting at 191.1⁰C.  
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                   [Fig.4.7 X-ray diffractogram of pure carbamazepine] 
Molecular arrangement of four different polymorphs of carbamazepine in fig 4.8- 
        
[Fig.4.8 Molecular arrangement in four polymorphs of carbamazepine from Grzesiak et al., 
2003] 
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However, commercially p-monoclinic form of carbamazepine (form III) is most frequently 
used in pharmaceutical formulation as it has highest solubility compared to other 
polymorphs. Moreover, except p-monoclinic form (form III), other three polymorphic forms 
of carbamazepine are found to be unstable. 
4.2.1.4 Density determination 
Grzesiak et al (2003) reported that stability of carbamazepine polymorphs is dependent on 
their density. They have suggested that the polymorph which possesses highest density is the 
most stable amongst all polymorphs of carbamazepine. They have concluded that p-
monoclinic form of carbamazepine has highest density (1.34g/cm3) and is the most stable 
polymorph. True density of pure carbamazepine was calculated by Helium pycnometry. Each 
sample was examined in triplicate and the average density of carbamazepine was found to be 
1.3312 g/cm3. 
4.2.1.5 Ultra-violet spectrophotometry 
The wavelength of maximum absorption (λmax) was determined by U.V. spectrophotometry. 
The obtained typical absorption spectrum of carbamazepine is shown in following figure 4.9. 
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                      [Fig.4.9 U.V. absorption spectrum of carbamazepine in methanol.] 
The wavelength of maximum absorption was determined by methanolic solution of 
carbamazepine. One large and one small peak were obtained at 220.13nm and 285.28nm, 
respectively. 
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4.2.2 Physicochemical characterisation of saccharin 
4.2.2.1 Vibrational spectroscopy 
4.2.2.1.1 IR spectroscopy 
The structural determination and confirmation of saccharin was accomplished by IR 
spectroscopy. Characteristic absorption bands (fig.4.10) and a description of characteristic 
infrared bands is given below. 
In FTIR spectra of saccharin, (-C=O) group is attached with –NH to form homomeric (- N-H 
----O=C) dimer. The –NH stretch and –C=O stretch of secondary amide is represented by 
corresponding two peaks at 3091.885 cm-1 and 1719.553 cm-1.  
The symmetric and asymmetric stretching of –SO2 group represents peak at 1177.965 cm-1 
and 1336.222 cm-1, respectively. 
       
                                [Fig.4.10 FTIR Spectra of saccharin] 
-NHstrech of 
sec. amide 
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(-C=O) strech 
ofsec.amide
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1336.222 assymmetric 
streching of -SO2 group
1177.965,
symmetric 
streching of -
SO2 group
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It has been mentioned before that in the saccharin molecule, the (-C=O) group is attached to 
the –NH to form homomeric (- N-H ----O=C) dimer (Jaysankar et al., 2010).   
4.2.2.1.2 Raman spectroscopy 
In the Raman spectra of saccharin (Fig. 4.11), the corresponding stretching vibrations for –
C=O group, -SO2 group and –NH group were observed at wave number 1698.71cm-1, 
1175.76cm-1 and 120.78 cm-1 (O’Brien et al., 2004) . 
Other types of vibrations like stretching, bending and rocking vibrations are described in the 
following table of description of Raman spectra (table 4.2). 
                                    [Fig.4.11 Raman spectrum of saccharin] 
Characteristic Peak                        Description of vibrational mode  
1698.71 Second order [C=O] stretching 
1594.600 [C-C] stretching along with [C-C-C] bending 
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1175.76 Very strong stretching of [-SO2] and [C-S-N] bending 
1016.49 Bending of [C-C-C] 
703.089 Bending of [C-C-C] 
521.25 Bending of [C-C-C] 
383.354 Rocking vibrations of [-SO2] 
173.938 Lattice vibrations 
120.78 [N-H stretching] 
                 [Table 4.2 Different types of vibrational modes in saccharin] 
4.2.2.2 Thermal analysis 
4.2.2.2.1 Thermo-gravimetric analysis 
Saccharin is most stable compound and hence, it is vital as a co-former.  Hence, to determine 
its onset of degradation, thermal screening was accomplished by using thermo-gravimetric 
analysis.  
The thermogram shown below in fig 4.12 illustrates that onset of degradation for saccharin 
starts at 150⁰C but, after 241.51⁰C fast degradation of saccharin was observed which was 
represented by rapid weight loss. Maximum degradation (i.e. 96.14%) occurs in range of 
241.51⁰C to 275.22⁰C.   
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                                [Fig.4.12 TGA thermogram of saccharin] 
4.2.2.2.2 Differential scanning calorimetry 
To determine heat flow pattern in saccharin, differential scanning calorimetry was performed. 
From fig. 4.13, it has been observed that onset of melting started at 227.71⁰C and was 
completed at 229.26⁰C employing normalised energy 152.8J/g. It has been reported in several 
research articles that saccharin possesses melting endotherm at 228+0.5⁰C. Identical results 
were obtained as per previously reported articles.  
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                              [Fig.4.13 DSC thermogram of saccharin]   
4.2.2.3 X-ray diffractometry      
To determine unique x-ray diffraction pattern of pure saccharin, x-ray diffractometry was 
accomplished. 
                                  
                              [Fig.4.14 X-ray diffractogram of saccharin] 
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The above x-ray diffractogram (fig. 4.14) of saccharin demonstrates three characteristic peaks 
of pure saccharin at, 2Ɵ= 16.14, 19.00 and 25.00. 
4.2.2.4 Density determination 
Density of pure saccharin was calculated by Helium pycnometer. Samples were analysed in 
triplicate and the average density of pure saccharin was found to be 1.5800 g/cm3. 
4.2.2.5 Ultra-violet spectrophotometry 
Wavelength of maximum absorption (λmax) of methanolic solution of saccharin (30μg/mL) 
was determined by U.V.spectrophotometer. 
 
                        [Fig.4.15 U.V. absorption spectrum of saccharin in methanol.] 
One prominent peak was obtained at 204.16nm which is characteristic maximum absorption 
wavelength (λmax) for saccharin (see 4.15). 
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4.2.3 Carbamazepine: saccharin (1:1) co-crystal 
Carbamazepine: saccharin (1:1) co-crystals were prepared using solvent crystallisation 
method reported by Hickey et al (Hickey et al., 2007). The prepared pure co-crystals of 
carbamazepine and saccharin were used for comparison with co-crystals prepared by TSE. 
The detailed procedure of solvent crystallisation is described in chapter 3 (section 3.2.7.1).It 
was found that during cooling of mixture from 70⁰C to 30⁰C, precipitation was started to 
occur from 59⁰C. The co-crystals were started to appear in a temperature range of 52⁰C to 
49⁰C followed by additional precipitation at 30⁰C. The recovery of co-crystal was found to 
be 13.56g.  
The co-crystallisation process consists of two major events, namely nucleation and crystal 
growth (Kelly and Rodrguez-Hornedo., 2009) Solute molecules dispersed within solvent 
form transient, unstable clusters, which re-dissolve under stirred conditions. Such clusters 
should first reach critical size in order to form stable nuclei. This process depends on 
operating conditions such as temperature, stirring rate and obviously supersaturation. At 
nucleation, atoms are arranged in defined periodic manners which finally define the crystal 
structure. Nucleation and crystal growth are simultaneous continuous processes.  Even 
though, crystal growth may predominate over nucleation or vice versa, depending on the 
supersaturation and temperature drop, which acts as driving forces for these processes. Such 
variations often give rise to different crystal size, shape or altogether crystal behaviour. As 
supersaturation is diminished due to bulk flow of the solute from solvated to crystalline 
phase, an equilibrium is established between concentration of solute in solvated form and that 
crystallized out, finally bringing the crystallization process to a halt.  
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4.2.4 Physicochemical characterisation of co-crystal 
4.2.4.1 Vibrational spectroscopy 
4.2.4.1.1 IR spectroscopy 
Infrared absorption spectrum of co-crystal was obtained by FT-IR spectrophotometer. 
Characteristic absorption bands (see fig.4.16) and description of characteristic IR- bands is 
given below. 
In saccharin molecule, (-C=O) group is attached with –NH to form homomeric (- N-H ----
O=C) dimer. In carbamazepine-saccharin co-crystal, -NH group of saccharin forms hydrogen 
bond with carbonyl group (-C=O) of carbamazepine to form heteromeric (- N-H ----O=C) 
dimer leaving carbonyl group of saccharin free. 
                [Fig.4.16 FTIR spectra of co-crystals prepared by solvent crystallization]  
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SO2 (O=S=O) group of saccharine, one S=O forms covalent bond with anti -NH of amide 
group of CBZ to form S=O--H-N in co-crystal and shows peak of –NH stretch of amide at 
3496.93 cm-1, while another S=O forms S=O---H-C within saccharin molecule. Asymmetric 
stretch of –SO2 group is represented by peak at 1330.67 cm-1. The peak shift is observed for 
carbonyl group from 1676.137 in CBZ to 1646.09 in co-crystal and –NH stretch of amide 
group of CBZ from 3464.14 to 3496.935 in co-crystal.  Peak shift is also seen corresponding 
to asymmetric stretch of –SO2 from 1336.222 in SAC to 1330.67 of co-crystal (Jaysankar et 
al., 2006). 
4.2.4.1.2 Raman spectroscopy 
Raman spectroscopy of pure co-crystals was carried out. The obtained Raman spectra and 
description of vibrational mode of characteristic peaks was given below in fig.4.17 and table 
4.3, respectively. 
                  [Fig.4.17 Raman Spectrum of Carbamazepine: saccharin co-crystal] 
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Characteristic 
Peak 
                       Description of vibrational mode  
1624.24 Non-aromatic [C=C] stretch 
1597.77 Secondary amide [N-H] bend, [C-C] stretching along with  
[C-C-C] bending 
1566.00 Aromatic [C=C] stretching 
1490.48 [C=C] symmetric stretching and aromatic [C-N] stretch 
1411.064 [C=C]stretch and [C-H] bend 
1309.07 Non-aromatic [C-H] in plane bending 
1252.21 [C-N] stretching of amide 
1219.06 [C-N] stretching of amide  
1028.44 In plane [C-H] aromatic bending. 
175.71 Lattice vibration 
120.98 [N-H] stretching 
           [Table 4.3 Different types of vibrational modes in CBZ: SAC co-crystal] 
The following fig. 4.18 demonstrates the formation of co-crystal peak in Raman Spectra. 
 
                              [Fig.4.18 Illustration of co-crystal formation] 
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 In co-crystal spectra (see fig.4.17); intensities of C-H bending at 1041.85 and 1024.04 
differed when compared to pure carbamazepine. Comparing with carbamazepine, peak 
intensities at 1041.85 cm-1 decreased by 263.0 while, at 1024.04 cm-1 it increased by 52781.7 
in the co-crystal. Furthermore, the prominent peaks obtained in the Raman spectra of co-
crystals correspond to carbamazepine: saccharin (1:1) co-crystal form I (O’Brien et al., 
2004). To understand co-crystal formation, Raman spectra of pure carbamazepine, saccharin 
and co-crystal were overlaid and displayed in fig.4.18 It can be easily observed that the 
corresponding characteristic peaks of carbamazepine and saccharin at 272.5 cm-1 and 246.0 
cm-1 were suppressed and a new peak was generated at 231.7 cm-1 which is a characteristic 
peak of carbamazepine: saccharin (1:1) co-crystal. 
4.2.4.2 Thermal analysis 
4.2.4.2.1 Thermo-gravimetric analysis 
Determination of onset of degradation was achieved by using thermo-gravimetric analysis. It 
is mandatory to verify the onset of degradation of carbamazepine: saccharin (1:1) co-crystal 
as a pre-formulation study. The thermogram obtained by TGA (see fig.4.19) and its 
description is given below. 
It can be observed that the co-crystal was more stable at high temperature compared to pure 
carbamazepine. The onset of degradation of co-crystal (form I) was found to be 167.41⁰C. 
The results are in agreement with the findings of Porter et al who reported onset of 
decomposition of co-crystal form I at 170⁰C (Porter et al., 2007). Weight loss of 50.10% was 
observed in a temperature range from 196.41⁰C to 233.38⁰C. 
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                      [Fig.4.19 Thermo-gravimetric analysis of CBZ: SAC co-crystal] 
It can be concluded that after co-crystallisation, onset of degradation of co-crystals was found 
to be different compared to that of the starting crystalline components. 
4.2.4.2.2 Differential scanning calorimetry 
The polymorph I of carbamazepine: saccharin (1:1) co-crystal has reported melting point at 
173.8⁰C while, polymorph II has 166.8⁰C (Porter et al., 2007). X- ray diffraction pattern 
confirm the presence of polymorph I. For further confirmation of co-crystal polymorph, 
thermal screening was accomplished using differential scanning calorimetry. 
The following thermogram (see fig. 4.20) showed that the co-crystals prepared from solvent 
crystallization exhibited a melting point of 178.33 ⁰C. So, it can be confirmed that the co-
crystals formed by solvent crystallization has polymorph I. The onset of melting was found to 
be 176.80⁰C and normalised energy was found to be 123.6J/g. 
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                 [Fig.4.20 DSC thermogram of pure co-crystal] 
It was observed that after co-crystallisation, co-crystal exhibited a different melting point 
than that of the starting material. 
4.2.4.3 X-ray diffractometry 
A co-crystal is a two component system, in which carbamazepine gets connected with 
saccharin by non-covalent hydrogen bonds. The (fig.4.21) shown below illustrates molecular 
arrangement of carbamazepine: saccharin (1:1) co-crystals.  
Two types of hydrogen bonding are present in co-crystal namely heterosynthon and 
homosynthon (Porter et al., 2008). Homosynthon formed by packing between two inversion-
related carboxamide groups in carbamazepine by hydrogen bonding (Porter et al., 2008). 
While, in heterosynthon hydrogen bonds are formed between saccharin (-N—H) and 
carbamazepine (-C=O) and this whole assembly of co-crystal is connected to other co-
crystals by separate hydrogen bonding. This additional hydrogen bond is formed between anti 
–N—H of carbamazepine and –S=O of saccharin (Porter et al., 2008). 
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[Fig. 4.21 Three dimensional representation of crystal packing in carbamazepine: saccharin 
(1:1) co-crystal I (a) and II (b) along with illustration of homo-synthons in carbamazepine: 
saccharin (1:1) co-crystal form I and hetero-synthon in co-crystal form II from Porter et al., 
2008] 
Depending on the type of synthon, carbamazepine: saccharin (1:1) co-crystals exist in two 
polymorphic forms in which form I is formed by homosynthon bonding and form II is formed 
by heterosynthon bonding.  
As mentioned above, two different polymorphs of carbamazepine demonstrates two distinct 
x-ray diffractometry pattern. The diffraction patterns of two polymorphs of carbamazepine: 
saccharin (1:1) co-crystal shown below (fig. 4.22) can be easily distinguished by first peak. 
Polymorph I which is formed by homosynthon shows a characteristic peak at 2Ɵ=6.88⁰ 
while, polymorph II which is formed by heterosynthon shows a characteristic peak at 
2Ɵ=4.80⁰ (Porter et al., 2008). 
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[Fig.4.22 XRPD patterns of CBZ: SAC co-crystals form I and II from Porter et al., 2008] 
Further confirmation of the polymorphic form of co-crystal achieved by solvent co-
crystallisation, x-ray diffractometry was accomplished. The obtained powder pattern is shown 
below. 
By comparing XRPD patterns of the solvent co-crystallisation derived co-crystals with 
standard PXRD patterns of carbamazepine: saccharin (1:1) co-crystal forms I and II, it can be 
concluded that x-ray diffractogram of pure co-crystals (prepared by solvent crystallization) 
resemble to carbamazepine: saccharin (1:1) co-crystal form I (homosynthon). 
The X-ray diffractogram (fig.4.23) of pure co-crystal showed prominent peaks at 2Ɵ=7.0 and 
2Ɵ=14.0 which are characteristic peaks of co-crystals form I. 
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[Fig.4.23 X-ray diffractogram of carbamazepine: saccharin (1:1) co-crystal prepared by 
solvent crystallization] 
4.2.4.4 Density determination 
The density of pure carbamazepine: saccharin (1:1) co-crystal was calculated by Helium 
pycnometry. Samples were analysed in triplicate and the average density of carbamazepine: 
saccharin (1:1) co-crystal was found to be 1.4289 g/cm3. 
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4.3 Reverse phase- high performance liquid chromatography (RP-HPLC) system for 
carbamazepine: saccharin (1:1) co-crystal. 
High performance liquid chromatography is a developed form of column chromatography for 
the separation and quantification of multi-component system according to their physico-
chemical properties. The underlying mechanism of reverse phase HPLC is associated with a 
separation of molecules according to the difference in their polarity. Comparably, non-polar 
compounds in analyte exhibit a higher affinity for the stationary phase than polar compounds. 
Thus, non-polar compounds get restrained for an extended duration in the column and 
consequently, polar compounds elute rapidly by means of the mobile phase (Trujillo et al., 
2000). Thus, in a validated RP-HPLC method, the retention time of analytes depend on 
unique parameters like the type of column utilized, nature and flow rate of mobile phase and 
other specific conditions. RP-HPLC is the most frequently used chromatographic technique 
for separation and quantification of drug molecules.  
Separation of compounds by HPLC is a partition phenomenon. In the RP-HPLC technique, 
keeping the column size unchanged, modification of the silica surface is accomplished by 
binding long hydrocarbon chain to make it non-polar. Most frequently, long hydrocarbon 
chains having carbon-8 or 18 are used to make the silica surface non-polar. On the other side, 
a polar solvent is used as a mobile phase for example, water or alcohols.  
When a sample matrix is injected into the chromatographic system, highly polar solute 
molecules which bear considerable affinity to the polar mobile phase and less attraction to 
non-polar stationary phase, elute rapidly through the column.  
In this manner, analytes get partitioned on the basis of intrinsic physico-chemical properties 
in distinct degrees of separation among mobile phase and stationary phase during analysis. 
When compounds get eluted from the column in distinctive component bands, then the 
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detector detects and monitors the compounds and analyses the results in the form of response 
versus time. Most commonly, silica having molecular weight less than 1000g/mol is used. 
But apart from silica, there are many other adsorbent materials like alumina, polymeric 
substrates, methacrylate, graphitized carbon etc are also used in HPLC column. 
4.3.1 Column selection 
There are various stationary phase packing materials employed for reverse phase 
chromatographic application, the majority of which are based on modified silica gel surface. 
In the case of simultaneous estimation of carbamazepine: saccharin (1:1) co-crystal, 
carbamazepine is lipophilic compound with less polarity and saccharin is hydrophilic 
compound with high polarity. In reverse-phase chromatography, the less polar constituent 
gets attracted toward the hydrophobic surface of bonded phase of column and results in rapid 
elution of high polar analytes. Silica has a relatively high surface area of 450-950m2/g with 
large pore volume 0.7-1.2 mL/g and thus, is successfully employed as an adsorbent stationary 
phase for reverse phase HPLC. Particle size, shape and surface area are important factors for 
analysis of drug. Pore diameter range of silica lies in 50-250A0. A reverse phase C18 column 
has been proved to be useful for lipophilic drug and thus C18 column was chosen for analysis. 
4.3.2 Mobile phase selection and factors affecting choice of mobile phase:- 
Selection of solvents for mobile phase preparation play a vital role in HPLC analysis and 
thus, the solvents should possess some ideal properties. Both drugs should possess solubility 
and stability in the solvents being used in mobile phase. Within possible extents, the solvent 
should be non-volatile, non-toxic and economical but, there are several factors discussed 
further which affects the choice of mobile phase. HPLC is a sophisticated and versatile 
analytical process in which a suitable interplay of various parameters play an important role 
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during analysis to accomplish the desired separation. It is necessary that mobile phase 
selection should be based on parameters such as the type of stationary phase chosen, physico-
chemical properties of analytes etc., to optimize a separation. 
Solvents in the mobile phase need to have high purity, less reactivity with stationary phase, 
low boiling point and low viscosity. It has been recommended that the pH of the mobile 
phase within the range 3.0-9.0 is important for avoiding damage to column. As the stationary 
phase gets coated with mobile phase, it should be pure. The mobile phase should be free from 
dissolved air and impurities, because it may cause column blockage, resulting in poor peak 
resolution and change in retention time. Impurities and dissolved air in the mobile phase can 
be successfully avoided by passing the mobile phase through a 0.45μ filter and degassing the 
solvents by ultrasonic vibrations under vacuum, respectively.  
Selection of nano-emulsion as a mobile phase:- 
Nanoemulsion liquid chromatography (NELC) is part of micellar liquid chromatography in 
which surfactant is added into the solvent in suitable concentration to form micelles. Nano-
emulsion liquid chromatography has been successfully used for separation and simultaneous 
estimation of hydrophilic and hydrophobic analytes (Althanyan et al., 2011). 
In this technique, separation is governed by partitioning mechanism in which carbamazepine 
and saccharin get separated in different degrees between mobile and stationary phase. The 
water insoluble lipophilic carbamazepine favours penetration into oil droplets because of 
non-rigid surface and accordingly, elution of carbamazepine is principally influenced by 
partitioning into oil droplets of nano-emulsion (Althanyan et al., 2011). Surfactant molecules 
adsorb on the stationary phase to form layer and cause secondary partitioning mechanism 
where analytes get partitioned in stationary and mobile phase as well as oil droplets of nano-
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emulsion. Highly hydrophilic saccharin solubilises largely in aqueous phase and hence elute 
rapidly. As a result, the retention of hydrophilic saccharin is completely controlled by 
interactions with stationary phase (Althanyan et al., 2011). In this way, nano-emulsion liquid 
chromatography separates carbamazepine and saccharin. 
4.3.3 Development of optimum mobile phase 
4.3.3.1 Surfactant and co-surfactant 
Formation of nano-emulsion is a result of careful selection and chemical nature of selected 
surfactant and co-surfactant (Li and Wang, 1999). In this method, sodium dodecyl sulphate 
(SDS) was used which is an anionic surfactant. Cationic surfactant was not useful in this case 
because it affects the retention time of polar analytes (Li and Wang, 1999). 1-butanol is used 
as a co-surfactant which helps to increase kinetics of nano-emulsion formation. The co-
surfactant gets attached to micelles to achieve a further reduction in interfacial free energy 
that results in increase in miscibility of oil and water in nano-emulsion (Jihu and Laurence, 
1997). The non-polar hydrocarbon part of the molecule is lipophilic and thus shows solubility 
in oil while, polar –OH or –COOH group are hydrophilic which shows solubility in water. 
The tendency of adsorption increases as alcohol chain-length increases. In this study, 
medium-chain alcohol has been used as a co-surfactant.  
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      [Fig. 4.24 Effect of SDS concentration on retention time of CBZ and SAC] 
Figure number 4.24. Illustrates retention time variations occurred with respect to change in 
SDS concentration in the mobile phase. It was found that increasing concentration of SDS 
resulted in decreasing retention time of carbamazepine and saccharin. At a concentration of 
0.5% (w/w), retention time for carbamazepine and saccharin was found to be 12.4 min and 
5.3 min, respectively. After increasing concentration of SDS up to a level of 1.0% (w/w) and 
1.5% (w/w), it has showed considerable decrease in RT for both components (see fig.4.2.4). 
It has been reported that the raise in concentration of surfactant could have a direct effect on 
solubilisation of analytes as well as their partition with the stationary phase (Althanyan et al., 
2011). Hence, it may have an effect on retention time of CBZ and SAC. However, an 
additional raise [2.0% and 2.5% (w/w)] of concentration of SDS did not show considerable 
decrease in retention time because SDS might have reached its saturation level.  
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   [Fig. 4.25 Effect of butanol concentration on retention time of CBZ and SAC] 
Different concentrations of butanol were examined (see fig. 4.25). The figure 4.25 illustrates 
the effect of change in butanol concentration in the range from 1% (w/w) to 5% (w/w) on 
retention time of CBZ and SAC. Increasing concentration from 1%-3% (w/w) showed a 
gradual decrease in RT of CBZ and SAC; however it was found that further increasing 
concentration [above 3% (w/w)] did not show significant change in RT of both. Hence, it 
may be concluded that addition of co-surfactant enhances solubilisation capacity and 
separation of compound until it reaches to its saturation level. 
4.3.3.2 Oil phase 
In o/w nano-emulsion, if length of oil chain is increased then solubility of oil in water gets 
decreased (Li and Wang, 1999). Considering this fact, octane was selected as an oil phase for 
preparation of the nano-emulsion mobile phase which has a short chain length. It has been 
seen that if the concentration of the oil phase is increased the number of oil droplets get 
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increased which results in better partition and retention time of lipophilic drug such as 
carbamazepine gets decreased (Althanyan et al., 2011). 
 
        [Fig. 4.26 Effect of octane concentration on retention time of CBZ and SAC] 
From figure 4.26, it was observed that change in oil concentration in mobile phase did not 
have a noticeable effect on retention of saccharin. However, a decline in the graph of CBZ 
demonstrates that, increase in oil concentration from 0.3%- 0.5 (w/w) leads to a considerable 
decrease in retention of carbamazepine from 11.7min to 10.1 min, respectively. Further 
increase in oil concentration did not have a considerable effect on retention of CBZ. 
4.3.3.3 Water phase (phosphate buffer) 
Change in molar concentration of buffer:- 
In O/W nano-emulsion HPLC, composition of aqueous phase is very high. In this study, the 
phosphate buffer has been used as an aqueous phase and consequently, molar concentration 
of buffer play important role. Four molar concentrations of phosphate buffer were examined 
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in the range 5mM- 25mM. It was observed that a change in molar concentration considerably 
affects retention time of CBZ and SAC (see Fig. 4.27). When concentration of the phosphate 
buffer was increased from 5mM to 20mM, retention time of CBZ and SAC was increased. 
These findings are contradict with with findings of Mao et al. (Mao and Carr, 2001) and 
Althanyan et al. (Althanyan et al., 2011). They have mentioned that retention time of 
protonated analytes decreased by increasing buffer concentration.  
  
       [Fig. 4.27 Effect of molar concentration on retention time of CBZ and SAC] 
It has been observed that lowest buffer molarity (5mM) lead to peak broadening of CBZ 
along with untimely elution of saccharin that give rise to an incomplete peak. Increase in 
molar concentration from 10mM to 25mM demonstrated a raise in retention time of CBZ and 
SAC (See fig.4.27). A 10mM buffer concentration was selected as an optimum concentration 
for the mobile phase because an inappropriate peak resolution of SAC and CBZ was observed 
at high molar concentration (20 and 25mM).   
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Change in pH of mobile phase:- 
Study of pH effect on retention time of analytes was examined at a range of pH 1 to 5. It was 
found that change in pH did not affect considerably affect retention time of carbamazepine 
since it is a neutral drug. 
 
             [Fig. 4.28 Effect of pH change on retention time of CBZ and SAC] 
It has been noticed that peak efficiency of saccharin and retention time was slightly increased 
by raising pH from 1- 3 (see Fig. 4.28). However, raising the pH value above three did not 
show any marked effect on saccharin.  
Hence, a phosphate buffer (10mM) having acidic pH 3.0 has been used as a water phase in 
nano-emulsion.  
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4.3.4 Particle size measurement of nano-emulsion 
Particle size of nano-emulsion was measured by using zetasizer. 
 
 
[Fig.4.29 Size distribution of nano-emulsion mobile phase with respect to volume and 
intensity] 
The above two graphs (in fig.4.29) illustrate globule size distribution in nanoemulsion with 
respect to intensity and volume, respectively. Polydispersity index (PDI) and average globule 
size of nanoemulsion was found to be 0.626 and 10.11nm, respectively.  
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4.3.5 Wavelength of detection 
The U.V. absorption maxima (λmax) for carbamazepine (30μg/mL) and saccharin (30μg/mL) 
are shown in the following figure 4.30. For detection of both the compounds, an iso-
absorption point was selected at λmax= 213nm. 
                  [Fig.4.30 Overlain U.V. spectra of carbamazepine and saccharin] 
Chromatographic conditions:- 
Mobile phase 
Nano-emulsion pH 3.0 (SDS-1.5%, octane-
0.7%, butanol-3%, phosphate buffer 10mM-
94.8%) 
Detection wavelength (λmax) 213nm 
Flow rate 1mL/min 
Injection volume 30μL 
Analytes ratio- CBZ:SAC 1:1 
Temperature of column At ambient temperature 
Retention time 
For CBZ-9.65 
For SAC-1.70 
                          [Table 4.4 Optimized chromatographic conditions] 
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4.3.6 Method validation 
Validation of the developed method was performed using International conference on 
harmonization (ICH) guidelines to simultaneously estimate carbamazepine and saccharin in 
co-crystal form.  
4.3.6.1 Specificity and selectivity  
In carbamazepine: saccharin (1:1) co-crystal, both components are present in a 1:1 molar 
ratio which is called the stoichiometric ratio. Both crystalline components are UV sensitive 
and consequently the method was found to be specific for analysis.  
The developed method was found to be selective for CBZ and SAC as shown in fig. 4.31. 
   
         [Fig. 4.31Chromatogram showing separation of saccharin and carbamazepine]  
The above fig. 4.31 showed distinctive separation of CBZ (35μg/mL) and SAC (35μg/mL). 
This illustrates that saccharin was eluted at 2.1min while, carbamazepine at 9.6 min. No 
interference of any peak was observed. 
 
 
Time (min) 
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4.3.6.2 Linearity and range 
Linearity of the method demonstrates the capability of the analytical method to illustrate 
proportionality of results which is directly proportional to analytes concentration by explicit 
mathematical transformation. According to ICH guideline, not less than five concentrations 
were required to be analysed, with a minimum of twenty assays to assure statistical validity. 
Linearity was determined by assessing eight samples in sixlet with concentration range of 
2μg/mL- 50μg/mL for both carbamazepine and saccharin which is shown below.  
     
                                  [Fig.4.32 Calibration curve for carbamazepine] 
 
                                 [Fig.4.33 Calibration curve for saccharin] 
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Regression coefficient line for area under the curve response verses concentration was plotted 
and used as a linearity assurance where the R2 value was found to be 0.9907 (fig.4.32) for 
carbamazepine and 0.9989 for saccharin (fig.4.33). In case of carbamazepine, linear equation 
was found to be y=3156.7x+4261.5 while, standard deviation for slope and intercept was 
found to be 0.0225 and 0.0570, respectively i.e. [y=3156.7 (+0.0225) x+4261.5(+0.0570)]. 
However, In the case of saccharin, the linear equation was found to be y=3278.6x-1812.5 
whereas, standard deviation for slope and intercept was found to be 0.0253 and 0.07622, 
respectively i.e. [y= 3278.6(+0.0253) x- 1812.5(+0.07622)]. 
4.3.6.3 Precision 
Precision is “degree of scatter or closeness of agreement within measurements of individual 
test results when test samples are applied repetitively in prescribed parameters.” (ICH 
guidelines, 2005). According to ICH guidelines it should be assessed by means of applying a 
minimum of five aliquots for each concentration and a minimum of three concentrations are 
expected. Precision is divided in intra-day precision which is repeatability and inter-day 
precision which referred as reproducibility. Degree of precision is expressed in percent 
relative standard deviation (%RSD). 
Repeatability or intra-day precision:- 
Repeatability of the analytical method attributed to intra-assay precision and was expressed in 
degree of deviation. It should be assessed by analysing minimum three concentration samples 
in triplet. In this study, seven different concentration ranges were analysed by repeating each 
samples five times (n=5) and standard deviation was calculated. Intra-day precision data for 
carbamazepine and saccharin is shown in table 4.5 and 4.6, respectively. 
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Concentration 
(μg/mL) 
Mean concentration 
(μg/mL) 
Standard deviation %RSD 
2 
 
1.98 0.070 0.057 
5 4.89 0.685 0.282 
10 9.92 0.098 0.022 
15 15.01 1.531 0.390 
20 19.79 0.114 0.248 
40 39.81 1.040 0.194 
60 59.99 0.650 0.263 
                     [Table 4.5 Intra-day precision data for carbamazepine]                       *(n=5) 
Concentration 
(μg/mL) 
Mean concentration 
(μg/mL) 
Standard deviation %RSD 
2 
 
1.97 0.711 0.050 
5 4.99 0.894 0.315 
10 9.96 0.995 0.417 
15 14.94 1.442 0.493 
20 19.83 1.249 0.754 
40 39.91 0.559 0.121 
60 59.98 0.538 0.316 
                         [Table 4.6 Intra-day precision data for saccharin]                           *(n=5) 
Repeatability of analytical method was assessed by analysing test samples in concentration 
range of 2μg/mL- 100μg/mL and standard deviation and %RSD was found to be in limit 
according to ICH guidelines. 
Reproducibility or inter-day precision:- 
 Reproducibility was calculated by analysing five different concentration ranges by repeating 
each samples three times (n=3) and standard deviation is calculated. Reproducibility of 
analytical method was assessed by analysing test samples in concentration range of 5μg/mL- 
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80μg/mL and standard deviation and %RSD was found to be in limit according to ICH 
guidelines. The data for CBZ and SAC is shown in table 4.7 and 4.8, respectively. 
Concentration 
(μg/mL) 
Mean concentration 
(μg/mL) Standard deviation %RSD 
5 4.93 1.772  
0.152 
 
10 9.94 1.815  0.417 
20 19.89 2.368  0.7548 
40 40.05 1.902  0.1212 
80 80.01 2.015  0.2413 
                     [Table 4.7 Interday precision data for carbamazepine]      *(n=3) 
Concentration 
(μg/mL) 
Mean concentration 
(μg/mL) Standard deviation %RSD 
5 4.97 1.627  
0.0159 
 
10 9.91 1.746  0.7264 
20 19.99 2.935  0.123 
40 39.94 1.213  0.1591 
80 79.98 2.662  0.1419 
                        [Table 4.8 Interday precision data for saccharin]              *(n=3) 
4.3.6.4 Recovery 
Recovery of carbamazepine and saccharin was calculated by preparing samples of known 
concentrations in three different concentration ranges viz; 80%, 100%, 120%. Each sample 
was injected in triplicate (n=3) and variation was examined by calculating relative standard 
deviation (%RSD). The % mean recovery was found to be 99.48±0.23 for carbamazepine and 
99.28±0.15 for saccharin which indicate that the proposed method is accurate for estimation 
of both compounds in co-crystal form. Data for CBZ and SAC is shown in table 4.9.  
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Drug 
Amount Added 
(%) 
Total amount 
(mg) 
Amount recovered (mg) 
±%RSD 
Recovery (%) 
CBZ 
80 
100 
120 
4.01 
5.02 
6.01 
4.0±0.15 
5.01±0.36 
6.1±0.20 
98.97 
99.40 
99.21 
SAC 
80 
100 
120 
4.02 
5.0 
6.01 
4.02±0.62 
5.09±0.41 
6.02±0.20 
98.96 
99.41 
99.21 
                         [Table 4.9 Data of recovery test]                                    *(n=3) 
4.3.6.5 Limit of quantification (LOQ) and Limit of detection (LOD) 
Limit of detection is shortly termed as lowest concentration at which analytical method can 
detect the analyte but not necessarily quantified and limit of quantification is shortly termed 
as lowest concentration at which analyte can be detect as well as quantified with accepted 
level of accuracy. To determine limit of detection, standard deviation and slope of calibration 
curve is used.  
                                      LOD= 3.3σ/S   
                                   LOQ= 10σ/S.............where, σ = standard deviation of y-intercept and 
S= slope of calibration curve.  
Name of drug LOD LOQ 
Carbamazepine 0.1μg/mL 0.4 μg/mL 
Saccharin 0.699 μg/mL 2.0 μg/mL 
                   [Table 4.10 LOD and LOQ values for carbamazepine and saccharin]                                              
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Limit of detection (LOD) for CBZ and SAC was found to be 0.1μg/mL and 0.699 μg/mL 
while, the limit of quantification (LOQ) for same 0.4 μg/mL and 2.0 μg/mL (see table 4.10). 
At quantitation limits, three samples of carbamazepine and saccharin were injected in sixlet 
(n=6) and relative standard deviation was calculated which was found in limit. 
4.3.6.6 Accuracy  
Accuracy of the method was determined by analysing three different concentration ranges of 
carbamazepine and saccharin namely low (5μg/mL), medium (20μg/mL) and high 
(50μg/mL). Accuracy was examined by comparing true concentration and the 
observed/calculated spike concentration showed in table 4.11.  
Drug Actual concentration 
(μg/mL) 
Observed concentration 
(μg/mL) 
% Accuracy 
CBZ 5 
20 
50 
4.965 
19.804 
49.443 
99.30 
99.02 
98.886 
SAC 5 
20 
50 
4.963 
19.913 
49.971 
99.26 
99.56 
99.94 
              [Table 4.11 Accuracy data for carbamazepine and saccharin] 
4.3.6.7 Analysis of carbamazepine: saccharin co-crystal 
Carbamazepine: saccharin co-crystals (10mg) prepared by solvent crystallisation were 
dissolved in 4mL of methanol and further diluted with distil water up to 100mL to make 
solutions 92.70μg/mL and 7.30μg/mL for carbamazepine and saccharin, respectively. The 
content of CBZ and SAC were found to be 99.94 % and 98.99 % with % R.S.D. of 1.3 ? 0.23 
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and 1.86 ? 1.08, respectively. The low % R.S.D. value indicated the suitability of this method 
for routine analysis of CBZ and SAC in pharmaceutical dosage form (table 4.12). 
Parameters CBZ SAC 
Amount (mg) 9.27 0.73 
Observed drug content 
(%)±S.D 
99.94 ? 1.43 98.99 ? 1.92 
% R.S.D 1.3 ? 0.23  1.86 ? 1.08 
                                                                                                      *(n=6) 
                             [Table 4.12 Analysis of co-crystal by NELC] 
 
4.3.7 Conclusion 
The isocratic O/W nano-emulsion liquid chromatographic method has been developed and 
validated for simultaneous estimation of carbamazepine and saccharin. The NELC possesses 
potential to solubilise along with partitioning of diversely polar compounds and hence 
separation. NELC has proven its suitability for routine analysis of carbamazepine: saccharin 
co-crystal. The developed NELC technique for carbamazepine and saccharin can be used 
over a wide range of mixture composition and can further be validated for pairs with 
dissimilar log P values.   
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4.4 Co-crystallisation assessment by twin screw extrusion (TSE)  
The TSE is a method which transfers the reacting components along the extrusion barrel 
under elevated temperature by means of rotating screws to prepare extrudates of desired 
shape by passing through a die (Crowley et al., 2007). It is a continuous process which 
involves high shear along with elevated temperature and thus twin screw extrusion was 
employed here for continuous co-crystallisation. 
4.4.1 Selection of extrusion processing temperature 
The selection of processing temperatures plays an important role during co-crystallisation 
since carbamazepine is a thermolabile drug. The above TGA and DSC thermograms 
carbamazepine, saccharin and co-crystal [Fig.4.4, 4.5, 4.12, 4.13, 4.19, 4.20] provide 
information concerning melting and onset of degradation which is revealed below. 
No. Component Melting point Onset of degradation 
1. Saccharin 229.26⁰C 150.51⁰C 
2. Carbamazepine 175.57⁰C 200.04⁰C 
3. CBZ:SAC (1:1) co-crystal 178.33⁰C 167.60⁰C 
            [Table 4.13 Thermal analysis data of starting components and co-crystal] 
The figure 4.34 shows the heat flow pattern of a physical mixture containing carbamazepine 
and saccharin in 1:1 molar ratio. The DSC thermogram reveals that 133.31⁰C is a eutectic 
point of carbamazepine and saccharin. A melting endotherm at 177.1⁰C demonstrates 
formation of some amount of CBZ: SAC (1:1) co-crystal in the physical mixture during 
heating.  
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            [Fig. 4.34 DSC thermogram of carbamazepine: saccharin (1:1) physical mixture]  
From table 4.13 and the DSC thermogram of physical mixture containing carbamazepine and 
saccharine Fig. 4.34, it can be concluded that to avoid the degradation of starting crystalline 
components in TSE induced co-crystallisation, the process needs to be carried out in a range 
of 130⁰-140⁰C. When heaters administer heat energy to the extrusion barrel, there might be 
some probability of heat loss during transmission from barrel to the screws and as a result 
screws will not get heated to the desired temperature. 
Considering this fact, a trial run of co-crystallisation using TSE was carried out. The 
extrusion barrel was heated to a temperature of 150⁰C, so that, subsequent to heat loss, 
screws will obtain desired heat energy (140⁰C). Configuration III (see table 3.6, page no. 52) 
was chosen for the experiment since, it is simple and provides medium shear which might be 
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helpful for checking the effect of temperature solely. The temperature of heating zone seven 
was adjusted to 150⁰C while, other heating zones were heated to a temperature same as that 
of temperature profile T-140 (see table 3.11, page no 55). The CBZ and SAC were mixed in 
1:1 molar ratio and fed into the conveying zone via a feeder. At a screw speed of 20 rpm and 
feed rate 2g/min, the residence time of physical mixture was found to be 12 min 15 seconds. 
The observed torque (10%) was found to be within limits. However, in this process, the 
starting crystalline components which are carbamazepine and saccharin were found to be 
degraded in the extrusion barrel. The following figure 4.35 shows the degradation of 
crystallizing components inside the heated extrusion barrel. 
 
           [Fig.4.35 Degradation of carbamazepine and saccharin physical mixture] 
It has been concluded that apart from the extrusion barrel temperature, shear between the 
twin screws and crystalline material generates some amount of heat which lead in 
degradation of carbamazepine and saccharin.  
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Thus, to avoid degradation of the starting materials, co-crystallisation was carried out at a 
temperature profile of 145⁰C. The temperature of heating zone seven was adjusted to 145⁰C 
while, other heating zones were set at a temperature same as that of temperature profile T-
140⁰C. All processing parameters like feed rate, configuration and screw speed were kept 
constant. Nevertheless, the residence time of physical mixture was found to be same and 
identical results were obtained as per previous co-crystallisation batch which was carried out 
at a temperature profile of 150⁰C. However, the amount of degraded product was found to be 
less compared to the temperature profile 150⁰C. The following fig. 4.36 shows degradation at 
the screw surface. 
  
                        [Fig. 4.36 Degradation at surface of the twin screws] 
From this study, it can be concluded that no heat loss was occurred during the heat transfer 
from heaters to twin screws, as it was observed that screws are getting heated exactly at set 
temperature. Moreover, material in the extruder barrel was getting exposed to shear along 
with elevated temperature and experienced additional generation of heat caused by shear 
effect of screws which lead to degradation.  
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To find out the maximum temperature for TSE induced co-crystallisation, the process was 
carried out at a temperature profiles T-140⁰C and T-130⁰C. The extrusion parameters like 
feed rate, screw configuration and screw speed were kept the same as that of previous 
experiments. Residence time of physical mixture for both batches was found to be 9 minutes. 
No degradation was observed in final product or in extrusion barrel. The observed torque was 
found to be within a range of 8-12%. Thus, both temperature profiles were found to be 
suitable for carrying out TSE induced co-crystallisation. Therefore, it can be concluded that 
140⁰C is a highest temperature for carrying out co-crystallisation process of carbamazepine 
and saccharin in TSE. Summary table (4.14) of this study is given below. 
Temperature 
(⁰C) 
Configuration Residence 
Time 
[min 
(sec)] 
Feed 
Rate 
(g/min) 
Screw 
Speed 
(rpm) 
Torque 
(%) 
Problem Result 
150 III 12(15) 2 20 10 Degradation 
In mixing 
zone 
Generation 
of extra 
heat 
because of 
shear 
145 III 12(15) 2 20 10 Degradation 
at screw 
surface 
Shear 
causes 
degradation 
140 III 9 2 20 8-12 No Accepted 
130 III 9 2 20 8-12 No Accepted 
   [Table 4.14 Summary of processing temperature effect on co-crystallisation by TSE] 
4.4.2 Establishment of extrusion process for co-crystallisation 
In TSE induced co-crystallisation, formation of co-crystals might be accomplished due to the 
high processing temperature of 130⁰C or 140⁰C. To verify whether co-crystallisation is an 
effect of temperature or temperature along with shear, a heat-cool-heat analysis was carried 
out using differential scanning calorimetry (DSC).  
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The figure 4.37 shown below demonstrates a thermogram obtained from heat-cool-heat 
analysis. The thermogram obtained from carbamazepine and saccharin (1:1 molar ratio) 
shows first a small endothermic peak at a temperature of 130.3⁰C which demonstrates 
eutectic temperature of the physical mixture and followed by an exotherm at 131⁰C. An 
isothermal test of CBZ: SAC (1:1) physical mixture was carried out at 140⁰C for 10 min and 
following cooling to the initial temperature. Subsequently, the thermogram shows two 
endothermic peaks at 156.71⁰C and 172.64⁰C and their respective normalised energy were 
found to be 19.69J/g and 15.60J/g.  The peak demonstrates possibility of intermediate 
formation and some quantity of pure co-crystals of carbamazepine and saccharin. 
  
              [Fig.4.37 Heat-cool-heat analysis of CBZ: SAC physical mixture (1:1)] 
It has been concluded that pure co-crystal formation cannot be achieved solely by exposing 
carbamazepine and saccharin to higher temperatures; however, shear is a prerequisite 
conjointly with temperature to effect rearrangement of the bonds which eventually results in 
hydrogen bonded co-crystals of carbamazepine and saccharin.  
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Single screw extrusion does not provide sufficient levels of shear as it is designed only for 
melting and conveying. Hence, it can be concluded that the twin screw extruder is mandatory 
for melt co-crystallisation of carbamazepine and saccharin. 
4.4.3 Effect of shear intensity 
It has been previously shown that co-crystallisation is a shear dependent process. But, the 
obligatory step is to determine the minimum prerequisite shear intensity which is required for 
co-crystal formation. Thus, to determine the required shear intensity, co-crystallisation using 
TSE was carried out from a range of very high shear intensity to moderate mixing intensity. 
To begin with, co-crystallisation was carried with screw geometry configuration I (see table 
3.4, page no 51) which provides very high shear. In this study, carbamazepine and saccharin 
were mixed in 1:1 molar ratio and added under the selected temperature profile and screw 
configuration. Moreover, all extrusion batches were carried out at a feed rate of 2g/min and 
screw speed of 20 rpm. In dissolution study, co-crystallisation batches carried out using TSE 
are coded by alphabetical letters (e.g. A, B, C and so on) in table no. 4.16. 
A batch was carried out by adding the physical mixture under a temperature profile T-140⁰C. 
The extruder barrel was found to be blocked and overshooting of torque was observed. The 
observed torque was fluctuating in the range of 58-82% which is considered to be very high. 
The physical mixture of carbamazepine and saccharin (1:1) in zone 4 was unable to move 
forward because of very high shear provided by 30⁰ and 60⁰ mixing paddles. The experiment 
could not be completed and residence time could not be measured. Because of very high 
shear (provided by 30⁰ and 60⁰ elements), forward conveying of the physical mixture was 
stopped which resulted in an increase in the residence time and lead to degradation. Hence, it 
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can be concluded that configuration I, providing very high shear is unable to achieve 
carbamazepine: saccharin (1:1) co-crystals.   
Hence, co-crystallisation was carried out with screw configuration II (high shear) to reduce 
the shear intensity and prevent degradation of carbamazepine and saccharin (see table 3.5, 
page no 52). The physical mixture was added to the twin screw extruder under temperature 
profile T-140⁰C. Co-crystals in the form of agglomerates were obtained and a residence time 
of the material was found to be 6 minutes. Although, identical results were obtained as with 
the previous experiment which was carried out using configuration I. The observed torque 
was found in range of 39-65% because of involvement of 0⁰, 30⁰ and 60⁰ mixing paddles in 
configuration. The overshooting of torque took place. As a result, screw rotation was stopped 
and the barrel was blocked. Since the residence time of physical mixture (inside the barrel) 
was increased and remaining physical mixture was degraded. In the dissolution studies, drug 
release profile of co-crystals in the form of agglomerates prepared by this batch is coded as 
batch-C (Table no. 4.16).  
The co-crystallisation achieved with configuration-II showed traces of pure co-crystal and a 
majority of unreacted components which is illustrated by using XRD. 
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         [Fig.4.38 PXRD pattern of agglomerates prepared by using configuration II] 
The x-ray diffraction reveals peaks at 2Ɵ=7.0 and 14.0 which are characteristic peaks of co-
crystals form-I while, peaks at 2Ɵ=13.36 and 2Ɵ=25.0 are characteristic peaks of p-
monoclinic form of carbamazepine and saccharin, respectively (see fig 4.38). This shows the 
presence of unreacted carbamazepine and saccharin in the extrudate. The peak at 2Ɵ=19.11 is 
characteristic peak of carbamazepine dihydrate which demonstrates that carbamazepine 
might have picked up moisture either during preparation of the physical mixture or after the 
processing. Analyzing the above results, it was concluded that the method is not appropriate 
for continuous co-crystallisation of carbamazepine and saccharin. 
Thus, co-crystallisation was carried out using configuration III which provides medium shear 
along with high dispersive mixing and staggered mixing. The physical mixture was added 
into the extruder at a temperature profile T-140⁰C.  The residence time of the powder was 
found to be 9 min and torque fluctuations were observed within a range of 4-7%. In the 
dissolution studies, drug release profile of co-crystals in the form of agglomerates achieved 
from this batch is coded as batch-D (Table no.4.16). During the process of co-crystallisation, 
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no interference was observed for example; overshooting of torque, screw blockage or 
degradation etc. The obtained extrudates were characterized by DSC (fig.4.40) and XRD (fig. 
4.39) to analyse formation of co-crystal as shown below- 
  
            [Fig.4.39 X-ray diffractogram of agglomerates prepared by configuration III] 
In the above XRPD pattern, a characteristic peak at 2Ɵ=7.0 confirmed the presence of 
carbamazepine: saccharin (1:1) co-crystal form I in the extrudate. The XRPD pattern also 
confirms absence of carbamazepine dihydrate. To examine the purity of co-crystals, 
differential scanning calorimetry (DSC) was carried out.  
A thermogram (fig. 4.40) achieved is shown below. 
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                   [Fig.4.40 Thermogram of agglomerates prepared by configuration III] 
The above thermogram shows two endothermic peaks at 156.69⁰C and 174.37⁰C in which the 
second endothermic peak corresponds to carbamazepine: saccharine (1:1) co-crystal form I. 
The endothermic peak at 156.69⁰C showed the presence of unreacted components during co-
crystallisation. Normalised energy for melting of co-crystal was found to be 75.43J/g. 
Accordingly, it can be concluded that the prepared co-crystals are impure and further 
modifications to the co-crystallisation process are necessary. Identical results were obtained 
when co-crystallisation using extrusion was carried out at a temperature profile T-130⁰C, 
keeping all parameters constant.  
During the process of co-crystallisation, torque fluctuation was observed within a range of 4-
7%. Moreover, no interference was observed for example; overshooting of torque, screw 
blockage and degradation etc. Hence, moderate shear intensity was selected as the optimum 
shear intensity for co-crystallisation. Summary table (4.15) of this study is shown below. 
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Shear 
intensity 
 
Configuration Residence 
Time 
[min 
(sec)] 
Feed 
Rate 
(g/min) 
Screw 
Speed 
(rpm) 
Torque 
(%) 
Problem Result 
Very high I Unable to 
measure 
2 20 58-82 Degradation 
In mixing 
zone 
Screw 
blockage, 
Overshooting 
of torque 
High II 6 2 20 39-65 Degradation 
in mixing 
zone 
Screw 
blockage, 
Overshooting 
of torque 
Medium III 9 2 20 4-7 No Accepted 
        [Table 4.15 Summary of effect of shear intensity on co-crystallisation by TSE] 
4.4.4 Effect of screw speed on co-crystallisation 
To increase the percentage purity of co-crystal, alteration of processing parameters was 
carried out. All co-crystallisation batches mentioned above were carried out at an extruder 
screw speed of 20 rpm. The extruder screw speed was reduced by 50% to increase the 
residence time of physical mixture in the extrusion barrel. Reduction of screw speed may 
result in increased contact between the physical mixture and mixing zones. Moreover, it may 
increase the residence time of components in the mixing zone so that physical mixture gets 
exposure to shear for a longer period of time, which might enhance the percentage purity of 
co-crystal. Along with change in screw speed, one additional change has been carried out in 
the temperature profile T-140⁰C. Temperature of zone 6 and zone 8 was increased by 10⁰C to 
hold the physical mixture at 140⁰C for an extended period (see Table 4.14). The physical 
mixture was added into the extruder and the experiment was carried out using screw 
configuration III. The speed of the extruder screw was adjusted to 10 rpm.  The residence 
time of the powder was found to be 11 min, at fluctuation of the torque was observed within a 
range of 9-24%. In dissolution study, the drug release profile of co-crystals in the form of 
agglomerates prepared by this experiment is coded as batch-E.  
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Different 
Zones in 
Extruder 
Barrel 
Zone 
10 
Zone 
9 
Zone 
8 
Zone 
7 
Zone 
6 
Zone 
5 
Zone 
4 
Zone 
3 
Zone 
2 
Temperature 
of zones 
 
110 
 
120 
 
140 
 
140 
 
140 
 
110 
 
75 
 
50 
 
25 
                        [Table 4.14 Minor alteration in Temperature profile T140⁰C] 
The purity of co-crystal in the form of agglomerates were analysed by differential scanning 
calorimetry. A thermogram achieved by DSC (See fig. 4.41) is shown below- 
   
             [Fig.4.41 Thermogram of agglomerates obtained at screw speed 10 rpm] 
The above DSC thermogram (fig. 4.41) of extrudates prepared by TSE at a screw speed of 10 
rpm demonstrates two endothermic peaks at 156.64⁰C and 174.08⁰C which illustrates the 
formation of pure carbamazepine: saccharin (1:1) co-crystal and presence of unreacted 
components, respectively. Normalised energy of melting endotherm of co-crystal was found 
to be 67.40J/g.   
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XRPD pattern of extruded sample prepared by 50% reduction of screw speed was shown in 
the figure 4.42. Peaks at 2Ɵ=7.0, 14.0, 15.36 and 19.56 demonstrates that extrudates were 
composed of co-crystals along with certain amount of unreacted carbamazepine and 
saccharin.  
  
     [Fig.4.42 X-ray diffractogram of agglomerates obtained at a screw speed of 10 rpm] 
It can be concluded that in the process of co-crystallisation using TSE, reduction in screw 
speed did not affect yield considerably and hence to achieve co-crystal with high percentage 
purity, further modification of the co-crystallisation process is necessary. Summary table 
(4.16) of effect of screw speed is shown below.   
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XRPD pattern of co-crystal prepared at 50% screw reduction 
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Screw 
Speed 
(rpm) 
Configuration Residence 
Time 
[min 
(sec)] 
Feed 
Rate 
(g/min) 
Torque 
(%) 
Problem Result 
20 III 9 2 4-7 Impure co-
crystals 
formed 
Process 
modification 
is necessary 
10 III 11 2 9-24 Impure co-
crystals 
formed 
Reduction in 
screw speed 
does not 
affect 
process 
          [Table 4.16 Summary for effect of screw speed on co-crystallisation by TSE] 
4.4.5 Effect of particle size on co-crystallisation  
To achieve co-crystals of high percentage purity, further modifications were made the co-
crystallisation process. The particle size of the starting crystalline components plays an 
important role in the crystallization process. Perhaps, there were chances of improving 
percentage crystallinity and purity of co-crystals provided that the co-crystallisation was 
carried out by varying particle size of the crystalline components. Carbamazepine and 
saccharin were divided into two different size ranges; fine particles (<250μ) and coarse 
particles (>250μ). The particle size reduction of carbamazepine and saccharin was 
accomplished by using jet mill micronizer. During particle size reduction of carbamazepine, 
the following results were obtained which are illustrated by DSC (fig. 4.43) and XRD (fig. 
4.44). 
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    [Fig.4.43 Thermogram of carbamazepine before (green) and after micronisation (red)] 
In the above diagram, two DSC thermograms (fig. 4.43) are exhibited namely pure 
carbamazepine (p-monoclinic form-III) which is presented in green and prepared micronized 
carbamazepine presented in red which resembles triclinic form-I of carbamazepine. 
As described earlier, carbamazepine exists in four polymorphic forms in which anhydrous p-
monoclinic (form III) is used as a starting material and it has melting point at 174⁰C and it 
gets re-crystallized at 176⁰C to form the Triclinic (form-I) form of carbamazepine which 
shows a melting point at 191⁰C (green). From the above DSC observed analysis, it appears 
that during micronisation at optimised parameters, process induced transformation of 
carbamazepine occurred which resulted in conversion of p-monoclinic form of CBZ into 
triclinic (form I) of CBZ, however this was shown not to be the case by PXRD (see fig. 4.44) 
of both starting and micronized material. 
Transition to form-I 
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 [Fig.4.44 XRPD pattern of micronized carbamazepine (black) and non-micronized 
carbamazepine (red)] 
The above XRPD (fig.4.44) pattern demonstrates two x-ray diffractograms, one for pure p-
monoclinic form-III of carbamazepine (red) and another for micronized carbamazepine 
(Black). The two diffractograms show identical characteristic peaks which correspond to p-
monoclinic form of carbamazepine. Thus, it can be concluded that jet milling of p-monoclinic 
form of carbamazepine does not encompass process induced transformation into triclinic 
form. But, the percent crystallinity of p-monoclinic form was found to have decreased and 
peak heights were a third of the starting material (p-monoclinic carbamazepine). In the DSC 
thermogram (see fig. 4.43), micronized carbamazepine does not demonstrate re-
crystallization like the pure starting material (p-monoclinic form of carbamazepine) because 
of decreased crystallinity and thus the recrystallization step was skipped. Jet milling lead to 
micronisation of particles where particle size is reduced significantly leading to conversion 
into the amorphous form (Patterson et al., 2005). The amorphous state consists of randomly 
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arranged molecules which are kinetically frozen. In contrast to the crystalline state they lack 
defined molecular order. On the provision of energy in DSC, which might be termed as 
barrier energy, these molecules get sufficient kinetic energy to be immobilised, interact and 
hence get converted into a stable crystalline form. In the case of carbamazepine x-ray 
diffractogram evidenced, the overall crystallinity decreased after jet milling. This 
significantly means that there must be conversion of carbamazepine into the amorphous form. 
This was also supported by DSC thermogram which did not exhibit a sharp melting 
endotherm and the lack of crystallization exotherm peculiar to p-monoclinic form III of 
carbamazepine.  
To study the effect of particle size on co-crystallisation kinetics, fine and coarse particles 
were separated by sieving method by employing a sieve of pore size 250μ. The physical 
mixture of coarse sized carbamazepine: saccharin (1:1) and fine sized carbamazepine: 
saccharin (1:1) was prepared and added into the extruder and experiment was carried out by 
using screw configuration III under temperature profile T-140⁰C.  The residence time of the 
powder was found to be 11 min. Fluctuation of the torque was observed within a range of 9-
24%. The extrudates were analysed by DSC (see fig. 4.45) and PXRD (see 4.46) which is 
shown below. 
The DSC thermogram illustrates heat flow pattern of co-crystals prepared by coarse and fine 
sized carbamazepine and saccharin, respectively. The co-crystal prepared by fine sized 
components showed two endothermic peaks at 156⁰C and 174.71⁰C, while that prepared by 
coarse sized components showed peaks at 156⁰C and 173.88⁰C. Normalised energy of 
melting endotherm of co-crystal prepared by fine sized and coarse sized components was 
found to be 77.68J/g and 76.47J/g, respectively. 
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  [Fig.4.45 DSC thermogram of fine (green) and coarse (red) powder derived extrudates] 
It can be observed that thermograms of co-crystals prepared using fine powder and coarse 
powder did not demonstrate any considerable difference in endothermic peaks. It can be 
concluded that in TSE derived co-crystallisation, utilization of crystalline components of 
variable size did not affect percentage purity of co-crystal. This was also supported by x-ray 
diffraction pattern of co-crystals prepared by coarse and fine carbamazepine and saccharin 
which is shown below. 
The PXRD pattern (Fig.4.46) shows a x-ray diffractogram of co-crystals prepared from 
carbamazepine and saccharin having coarse (black) and fine (red) particle sizes. Co-crystals 
represent the peak at 2Ɵ=7.0. It can be seen that the intensity (counts) of the characteristic 
peaks of carbamazepine: saccharin co-crystal (1:1) is almost the same in co-crystals prepared 
by both fine and coarse sized physical mixtures. 
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     [Fig.4.46 X-ray diffractogram of fine (red) and coarse (black) powder derived extrudates] 
The intensity of characteristic peak of co-crystal at 2Ɵ=7.0 was found to be less by 2.24 
counts in fine sized component mixture derived co-crystal than coarse sized component 
derived co-crystals. Thus, it can be concluded that particle size of crystalline components did 
not have substantially affect on TSE derived co-crystallisation kinetics. The drug release 
profile of extrudates prepared by fine sized and coarse sized starting components are 
described by letters G and F (Table 4.16), respectively in dissolution studies.  
4.4.6 Effect of addition of organic solvents  
It has been reported in several scientific research articles that the addition of small amount of 
organic solvent during solid state co-crystallisation enhances the reaction kinetics. Hence, in 
the TSE derived co-crystallisation process, a study of solvent addition is divided into two 
parts; first by the addition of a highly polar organic solvent and second is the addition of a 
non-polar organic solvent. Methanol was selected as the polar solvent while, toluene was 
selected as the non-polar.  
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4.4.6.1 Addition of highly polar organic solvent 
To enhance the kinetics and promote co-crystal formation, the method was modified with 
solvent addition using analytical grade methanol. By using temperature profile T-130 and T-
140, co-crystallisation was carried out using configuration III. Carbamazepine (21g; 0.089 
mol) and saccharin (16.3g; 0.089 mol) in 1:1 molar ratio were mixed to prepare the physical 
mixture and methanol was added in 5% of total weight of the physical mixture.  
It has also been noted that even if in ambient conditions, significant shearing force above a 
threshold is applied to the components during preparation of the physical mixture then there 
are chances of transformation to occur from physical mixture to co-crystal (Blagden et al., 
2008). So, to assure that the pre-milled or pre-mixed components were not co-crystals, PXRD 
patterns of prepared physical mixture were taken before the co-crystallisation process. The 
following XRD pattern (fig 4.47) confirms that the prepared physical mixture did not contain 
co-crystals. 
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                           [Fig.4.47 PXRD pattern of pre-mixed physical mixture] 
The physical mixture was added into the extruder. Residence time of the powder was found 
to be 5 min 45 sec in both processes. Fluctuation of torque was observed within a range of 8-
12% in temperature profile T-140 while the recorded torque during processing with 
temperature profile T-130 was 12% which remained constant throughout the co-
crystal0lisation experiment. Overshooting of torque or screw barrel blockage was not 
observed.   
In both experiments, sample collection was carried out at two different times particularly, 
during feeding and after feeding has stopped, as shown in the following table 4.15. X-ray 
diffractometry of collected four samples were carried out which is shown in fig. 4.48. 
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No. Methanol addition in 
Physical mixture (PM) 
Configuration Temperature Collection condition 
During process 
1. 5% of total weight of PM III 140⁰C During feeding 
2. 5% of total weight of PM III 140⁰C After stop feeding 
3. 5% of total weight of PM III 130⁰C During feeding 
4. 5% of total weight of PM III 130⁰C After stop feeding 
                    [Table 4.17 Processing parameters and sample collection conditions] 
  
[Fig. 4.48 X-ray diffractogram of samples achieved by temperature profiles T-130 and T-140] 
In every x-ray diffraction pattern evidenced (fig. 4.48), the obtained prominent peak at 
2Ɵ=7.0 is the characteristic peak of carbamazepine: saccharin (1:1) co-crystal. The co-
crystallisation batches taken at T-130⁰ and T-140⁰ showed appearance of prominent co-
crystal peak along with suppression of characteristic peaks of carbamazepine and saccharin. 
The DSC thermogram (fig. 4.49) shows heat flow patterns of four samples of co-crystals 
prepared by using temperature profiles T-130⁰C and T-140⁰C. The thermograms demonstrate 
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that for all samples of co-crystals, onset of melting was in the range of 171.70⁰C to 174.09⁰C. 
The melting endotherm of all co-crystal samples varied between 174.53⁰C-175.62⁰C which 
corresponds with the melting point of carbamazepine: saccharin (1:1) co-crystal.  
                 [Fig.4.49 Overlain of DSC thermograms of co-crystal samples] 
The enthalpy energy (J/g) to melt co-crystals prepared at temperature profile T-130⁰C during 
the first 20 min and on final 5 min was found to be 124.4J/g and 128.5 J/g, respectively and at 
temperature profile T-140⁰C for corresponding times was found to be 127.1 J/g and 130.7 
J/g. The insignificant variation between onsets of melting point and energy intake of each 
sample was varying because of a small amount of unreacted components. Thus, the addition 
of methanol in physical mixture showed enhancement of kinetics of co-crystallisation and 
promoted formation of co-crystals. In dissolution studies, the drug release profile of pure co-
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crystals in the form of agglomerates prepared by T-130⁰C and T-140⁰C was coded as batch-I 
and batch-H (Table 4.16), respectively. 
After monitoring and comparing the x-ray diffractogram (Fig. 4.48) and DSC (Fig. 4.49) 
thermograms, it can be concluded that co-crystallisation is independent of minor variations in 
temperature, but significantly depends on addition of a highly polar solvent (methanol) in the 
co-crystallisation process. Co-crystals in the form of agglomerates were successfully 
produced by using screw configuration III. Solvent addition proved to be an important factor 
responsible for formation of pure co-crystals. Configuration III along with 5% methanol 
showed highest co-crystal purity and addressed the problem of torque overshooting.  
At and above the eutectic temperature of the physical mixture (133.31⁰C), an intermediate 
melt phase is produced in mixing zone which facilitates mass transfer. Hence, molecular 
collisions between carbamazepine and saccharin are increased, which resulted in co-crystal 
growth. The temperature profile nearer to eutectic temperature point (130⁰C) causes 
metastable submerged point formation, which force these two components together to form a 
melt. The mixture is then seeded by the remaining physical mixture which results in 
successful co- crystallization.  
4.4.6.2 Addition of a non-polar organic solvent 
It has been reported that enhancement in kinetics of co-crystallisation was not be observed 
after minor addition of non-polar solvents during solvent drop solid-state ball-milling process 
(Hickey et al., 2007). Hence, from previously reported list of such solvents, toluene was 
selected. In TSE, thermal energy along with shear is employed unlike ball-milling and hence, 
there was a probability of formation of co-crystals in twin screw extruder due to minor 
addition of non polar solvent. Considering this, TSE derived co-crystallisation was carried 
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out using 5% toluene addition at both temperature profiles T-130 and T-140 by using screw 
configuration III. CBZ (21g; 0.089 mol) and SAC (16.3g; 0.089 mol) in 1:1 molar ratio were 
mixed to prepare the physical mixture and toluene was added at 5% of total weight of the 
physical mixture. Physical mixture was added into the extruder and experiments were carried 
out.  Residence time of the powder was found to be 5 min 10 sec for both processes.  
Fluctuation of torque was observed within a range of 4-5% in temperature profile T-140 and 
4% at T-130⁰. Prepared extruded product in the form of agglomerate was characterised by 
XRD (fig. 4.50) and DSC (fig. 4.51) which are shown below. 
           [Fig.4.50 X-ray diffractogram agglomerates prepared by 5% toluene addition]  
In the above x-ray diffractogram, a peak at 2Ɵ=7.0 demonstrates formation of 
carbamazepine: saccharin (1:1) co-crystal using 5% of toluene during the extrusion process. 
Two peaks at 2Ɵ=15.36 and 19.56 show the presence of unreacted carbamazepine while, a 
peak at 2Ɵ=25.0 represents the presence of unreacted saccharin. 
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         [Fig.4.51 DSC thermogram of agglomerates prepared by toluene addition]  
DSC thermograms (fig. 4.51) support this evidence of presence of unreacted material which 
was proven by two melting endotherm at 156⁰C and 158⁰C before the melting endotherm of 
co-crystal at 176⁰C. Normalised energy of the co-crystal endotherm prepared by 130⁰C and 
140⁰C temperature profile was found to be 94.37J/g and 99.82J/g, respectively. It can be 
concluded that toluene enhances co-crystallisation process in the presence of shear along with 
elevated temperature by TSE, but not in the cold conditions in ball-milling. In dissolution 
studies, drug release profile of agglomerates prepared by T-130⁰C and T-140⁰C were coded 
as batch-K and batch-J (Table 4.16), respectively.  
4.4.7 Effect of starting material variation and added water  
Some case studies revealed that similar to organic solvent, addition of water also enhances 
reaction kinetics of co-crystallisation. Hickey et al. reported that water increase co-
crystallisation kinetics of carbamazepine and saccharin during solvent assisted solid state 
ball-milling even at cold conditions (Hickey et al., 2007). The underlying principle of 
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improvement in kinetics is the formation of carbamazepine dihydrate after water addition 
which acts as an intermediate and speeds up the process. Scrutinizing this fact, instead of 
carbamazepine as a starting component, carbamazepine dihydrate was used along with 
saccharin in a physical mixture. Carbamazepine dihydrate is a most stable form and it has a 
higher molecular weight than carbamazepine. It is a solid dry powder which contains exactly 
5% of water bonded in the carbamazepine molecular lattice. Carbamazepine dihydrate was 
prepared by the method reported by McMahan et al. 1996 (McMahan et al., 1996). The 
carbamazepine dihydrate was characterised by XRD (fig. 4.52) and DSC (fig. 4.53) which is 
described below. 
 
              [Fig.4.52 X-ray diffractogram of pure carbamazepine dihydrate] 
The x-ray diffractogram showed prominent peaks at 2Ɵ=9.0 and 2Ɵ=2.36 which are 
characteristic peaks of carbamazepine dihydrate. 
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                    [Fig.4.53 DSC thermogram of carbamazepine dihydrate] 
From the DSC thermogram (fig. 4.53), it was seen that the onset of ‘water of crystallization’ 
was started at 25⁰C and total water removal was seen in the range of 56⁰C to 90⁰C. The 
normalised energy required for water of crystallization was found to be 251.3J/g. The 
dihydrate prepared from p-monoclinic form gave a very small endotherm near 160⁰C 
followed by a melting endotherm at 191⁰C which represents the characteristic melting point 
of the triclinic form (polymorph I) of carbamazepine. The energy utilized for melting of 
triclinic form I of carbamazepine was found to be 95.54J/g. Thus, after heating, dihydrate 
prepared from p-monoclinic form gets converted into triclinic form by loosing water from the 
crystal lattice. Thus, it can be concluded that water molecules encompasses a weak 
association within the crystal lattice of dihydrate. For employing carbamazepine dihydrate 
and saccharin as a starting crystalline component several changes were made to the TSE 
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process. Screw geometry was changed from configuration III to configuration IV-Reverse 
Elements (RE) but, shear mixing intensity was kept constant.  
4.4.7.1 Use of reverse elements to modify the co-crystallisation process 
Reverse elements were added to screw configuration to increase residence time and the 
process was conducted at a temperature profile 140⁰C. There might be difference between co-
crystallisation derived by CBZ: 2H2O and externally 5% water addition in physical mixture 
of CBZ and SAC. Thus, to evaluate the difference between both types of co-crystallisation, 
TSE derived co-crystallisation was carried out keeping all parameters constant.  Both co-
crystallisation processes were carried out at an extruder screw speed of 20 rpm and feed rate 
2g/min. Residence time of the physical mixture inside barrel in both experiment was same 
and found to be 11 min while, the observed torque was in the range 8-17%. Co-crystallisation 
was carried out successfully and obtained co-crystals in the form of agglomerates were 
studied by DSC (see fig. 4.54) and XRD (see fig. 4.55). 
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 [Fig.4.54 DSC thermogram of co-crystal prepared by carbamazepine dihydrate and 5% water 
addition]  
The above DSC thermogram (fig. 4.54) demonstrates two graphs of co-crystal samples 
prepared by carbamazepine dihydrate and 5% external water addition in physical mixture, 
respectively. DSC analysis confirmed that both processes had the potential to achieve pure 
co-crystals which gives a single endothermic peak at 175.1⁰C. The co-crystal prepared by 5% 
water addition, showed a normalised energy of 124.0J/g for melting while, those prepared by 
carbamazepine dihydrate showed a normalised energy of 155.8J/g. 
         Carbamazepine dihydrate +saccharin 
                         5% water addition in CBZ + SAC physical mixture 
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[Fig.4.55 X-ray diffractogram of co-crystals prepared by configuration IV-RE along with 
carbamazepine dihydrate and 5% water addition] 
In the above XRPD pattern (fig. 4.55), a prominent peak at 2Ɵ=7.0 reveals formation of pure 
co-crystal. An x-ray diffraction pattern of corresponding samples support the evidenced data 
of the DSC thermogram. Both co-crystal samples were found to be pure and having absence 
of unreacted carbamazepine and saccharin. In dissolution studies, drug release from pure co-
crystals in the form of agglomerates prepared by using carbamazepine dihydrate and 5% 
water addition was coded as batch-M and batch-L (Table 4.16), respectively. 
4.4.7.2 Effect of small alteration in screw configuration  
After achieving successful co-crystal formation by IV-RE screw geometry, it was essential to 
check even if any small alteration in screw geometry caused changes to the co-crystallisation 
process or not. The small change in screw configuration of IV-RE was accomplished by 
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changing one 60⁰ screw element by 30⁰ screw element which promotes conveying of 
physical mixture along with dispersive mixing.  
Thus, keeping shear intensity constant, a small change in screw configuration was arranged 
and named as configuration V-RE (moderate shear). The co-crystallisation process was 
carried out with configuration V-RE screw geometry by keeping all processing parameters 
identical as per the above co-crystallisation process conducted by configuration IV-RE. Co-
crystallisation studies were carried out by configuration V-RE using carbamazepine dihydrate 
along with saccharin and 5% external water addition in physical mixture as a starting 
component. In both processes, feed rate was kept constant at 2.0/min at screw speed 20 rpm 
using temperature profile T-140⁰C. Residence time of the physical mixture was found to be 8 
min15 sec and torque was observed in range 12-16% for both experiments. The co-
crystallisation process was accomplished successfully and co-crystals were collected and 
characterised by x-ray diffractometry (fig. 4.56) along with differential scanning calorimetry 
(fig. 4.57) which are described below. 
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[Fig.4.56 X-ray diffractogram of co-crystals prepared by configuration V-RE by using 
carbamazepine dihydrate and 5% water addition] 
  
[Fig.4.57 DSC thermogram of co-crystal prepared by configuration V-RE along with 
carbamazepine dihydrate and 5% water addition] 
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The above PXRD pattern (fig. 4.56) possesses characteristic peak at 2Ɵ=7.0 demonstrating 
successful formation of co-crystals. The small change in screw configuration of IV-RE was 
accomplished by changing one 60⁰ mixing paddle by 30⁰ mixing paddle to promote 
conveying of the physical mixture along with dispersive mixing. However, no significant 
alteration to the co-crystallisation process was observed. The purity of co-crystals was also 
determined by DSC (fig. 4.57) which is shown above. A single prominent endothermic peak 
was observed at 175.1⁰C which corresponds to pure co-crystal of carbamazepine and 
saccharin. Normalised energy of co-crystal for achieving a single endothermic peak was 
found to be 141.5J/g while, that of prepared by 5% water addition was found to be 133.6J/g. 
Both processes yielded pure co-crystals and it has been proved that a small change in screw 
geometry did not affect the co-crystallisation process if a process is performed in the presence 
of solvent. The starting component and water addition plays a vital role to enhance the 
reaction kinetics of co-crystallisation which results in formation of pure co-crystals. This has 
been proved from DSC thermograms of four co-crystals prepared by screw geometries IV-RE 
and V-RE (employing dihydrate form of carbamazepine and 5% water addition). It has been 
observed that co-crystals prepared from dihydrate possess higher purity and crystallinity as it 
showed a higher enthalpy in DSC thermograms than those prepared by 5% water addition. 
The purity of co-crystals prepared by 5% water addition was lower because, the method 
involves external addition of water which may be unable to assure formation of 100% 
dihydrate form of CBZ in the physical mixture and there was the probability of a presence of 
anhydrous carbamazepine in the physical mixture. However, in the case of pure 
carbamazepine dihydrate, water from the crystal lattice gets evaporated at temperatures 
between 50-90⁰C i.e. between mixing zone 3 and 4 which results in the formation of 
hydrogen bonds with saccharin to form co-crystals. The following fig. 4.58 supports this 
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evidence of evaporation of water at zone 3 and 4 which was taken after completion of co-
crystallisation process.  
   
                 [Fig.4.58 Adsorbed water droplets inside extrusion barrel]               
4.4.7.3 Study of cross-checking of reverse elements effect                      
To check whether the achieved co-crystallisation in the above IV-RE and V-RE batches was 
due to the effect of reverse elements or not, co-crystallisation was carried out with same 
configurations but without reverse elements. Both co-crystallisation processes were carried 
out at extruder screw speed 20 rpm with feed rate 2g/min in presence of 5% water.  Co-
crystallisation was carried out at temperature profile T-140⁰C. Residence time was found to 
be 5 min 10 seconds and torque was observed in the range 4-6%. Co-crystallisation was 
carried out successfully without any interference. Extrudates were achieved in form of 
agglomerates which were characterised by PXRD (fig. 4.59) and DSC (fig. 4.60) which are 
shown below- 
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[Fig.4.59 PXRD pattern of agglomerates prepared by configuration without reverse elements]  
The above diagram shows PXRD patterns (see fig. 4.59) of extrudates derived by a screw 
arrangement without reverse elements i.e. screw geometry IV-WRE and V-WRE. It has been 
observed that screw configurations without reverse elements failed to prepare co-crystals as 
the typical characteristic peak of co-crystal at 2Ɵ=7.0 were not observed in x-ray diffraction 
pattern. This result was supported by differential scanning calorimetry (fig. 4.60). 
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[Fig.4.60 DSC thermogram of extrudates prepared by configuration IV-WRE and V-WRE 
which are not containing reverse elements] 
The above DSC thermogram (fig. 4.60) shows heat flow patterns in extrudates prepared by 
screw geometry IV-WRE and V-WRE, respectively. From both thermograms it was observed 
that unreacted carbamazepine and saccharin were present in the extrudate. Only a small 
amount of co-crystals were formed demonstrated by a small endothermic peak at 175.3⁰C. 
The two endothermic peaks of co-crystal at 157.03⁰C and 173.68⁰C in the thermogram of IV-
WRE showed respective normalised energy 100.9J/g and 19.63J/g while, co-crystals prepared 
by V-WRE exhibits two melting endotherm at 157.51⁰C and 173.18⁰C which show 
normalised energy 48.25J/g and 10.45J/g, respectively. As the obtained extrudates were not 
co-crystals, they were not subjected to dissolution tests. 
Thus, it was confirmed that only 5% water addition was not solely responsible for successful 
co-crystal formation, but also a screw configuration containing reverse elements. This fact 
might crop up ambiguity for application of elevated temperature during TSE derived co-
 Development of a solvent free continuous co-crystallisation technique for carbamazepine-saccharin         Page | 144  
crystallisation process for solvent addition. Therefore, it was essential to verify whether 
elevated temperature played a substantial role or not during 5% addition of water during co-
crystallisation.  
4.4.7.4 Study of cross-checking of elevated temperature’s effect 
In order to verify whether the co-crystallisation process carried out by 5% water was 
temperature dependent, the same process was carried out using screw configuration IV-RE 
and V-RE but at room temperature (16⁰C). Like the processes which have been described 
before, water was added externally in 5% to the total weight of the physical mixture of 
carbamazepine and saccharin. Both crystallization processes were carried out at screw speed 
20 rpm and feed rate 2g/min. Residence time of material was found to be 10min 10seconds 
and the observed torque was in the range 36-48%. Extrudates of the process conducted by 
screw geometry V-RE were obtained successfully but, IV-RE could not be completed 
because of the high number of 60⁰ and 90⁰ screw elements. During the experiment using IV-
RE, overshooting of torque was observed as barrel became blocked and the process was 
stopped. Extrudates obtained during processing using V-RE configuration were characterized 
by DSC (fig. 4.61) and PXRD (fig. 4.62) which is described below. 
The following DSC thermogram (fig. 4.61) shows heat flow patterns in co-crystal prepared 
by configuration V-RE at room temperature. A single melting endotherm at 175.76⁰C was 
observed which resembled the melting point of carbamazepine: saccharin co-crystal. The 
onset of melting of co-crystal prepared at room temperature was found to be 173.18⁰C and 
utilized 132.5J/g energy for melting endotherm.  
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[Fig.4.61 DSC thermogram of co-crystal prepared by V-RE configuration at room     
temperature] 
 
 [Fig.4.62 X-ray diffraction pattern of co-crystal prepared by V-RE configuration at room 
temperature] 
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Solvent/Starting 
material 
variation 
Temperature 
(⁰C) 
configuration Retention 
Time [min 
(sec)] 
Torque 
(%) 
Problem Result 
Methanol 140 III 5 (45) 8-12 No Pure co-
crystals 
obtained 
130 III 5 (45) 12 No Pure co-
crystals 
obtained 
Toluene 140 III 5 (10) 4-5 Impurity 
found 
Process 
modification 
necessary 
130 III 5 (10) 4 Impurity 
found 
Process 
modification 
necessary 
CBZ: 2H2O 140 IV-RE 11 8-17 No Pure co-
crystals 
obtained 
Water 140 IV-RE 11 8-17 No Pure co-
crystals 
obtained 
CBZ: 2H2O 140 V-RE 8 (15) 12-16 No Pure co-
crystals 
obtained 
Water 140 V-RE 8 (15) 12-16 No Pure co-
crystals 
obtained 
Water 140 IV 5 (10) 4-6 Impurity 
found 
Reverse 
elements are 
mandatory 
140 V 5 (10) 4-6 Impurity 
found 
Reverse 
elements are 
mandatory 
Water 16 V-RE 10 (10) 36-48 High 
torque 
Pure co-
crystals 
obtained, but 
process 
unacceptable 
*Feed rate = 2g/min 
*Screw speed = 20 rpm 
              [Table 4.18 Summary for effect of solvent on co-crystallisation by TSE]  
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4.4.8 Dissolution Testing 
The pharmaceutical performance of co-crystals prepared by TSE in the form of agglomerates 
was examined by in-vitro dissolution tests and drug release is compared with pure 
carbamazepine and pure co-crystals prepared by solvent crystallisation. Dissolution profiles 
of pure carbamazepine, pure co-crystal and co-crystals in form of agglomerates prepared by 
different extrusion batches were displayed in fig.4.63, 4.64 and 4.65.  
The dissolution study was separated into three different parts; dissolution of extrudates 
prepared without solvent addition, extrudates prepared by addition of organic solvents like 
methanol and toluene and extrudates prepared by using 5% water addition and carbamazepine 
dihydrate as a starting component.  
In dissolution studies, percent drug release of every extrudate is represented by alphabetical 
letters while, its corresponding extrusion parameters represented symbolically. Batches were 
coded as shown in table 4.16. 
Batcch Batch description  
Batch- A Pure CBZ   
Batch-B Pure co-crystal (by solvent crystallization) 
Batch-C co-crystals (T 140: Configuration II: 20 rpm: WRE) 
Batch-D co-crystals (T 140: Configuration III: 20 rpm: WRE) 
Batch-E co-crystals (T 140*: Configuration III: 10 rpm: WRE) 
Batch-F co-crystals (T 140: Configuration III: 20 rpm: Coarse size: WRE) 
Batch-G co-crystals (T 140: Configuration III: 20 rpm: Fine size: WRE) 
Batch-H co-crystals (T 140: Configuration III: 20 rpm: 5% methanol: WRE) 
Batch-I co-crystals (T 130: Configuration III: 20 rpm: 5% methanol: WRE) 
Batch-J co-crystals (T 140: configuration III: 20 rpm: 5% toluene: WRE) 
Batch-K co-crystals (T 130: configuration III: 20 rpm: 5% toluene: WRE) 
Batch-L co-crystals (T 140: configuration IV: 20 rpm: 5% water: RE) 
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Batch-M co-crystal (T 140: configuration IV: 20 rpm: CBZ-2 H2O: RE) 
Batch-N co-crystal (T 140: configuration V: 20 rpm: 5% water: RE) 
Batch-O co-crystal (T 140: configuration V: 20 rpm: CBZ-2 H2O: RE) 
Batch-P co-crystal (RT: Configuration V: 20rpm: CBZ-2 H2O: RE) 
         [Table 4.19 Specific code for co-crystallisation batches and batch specifications] 
 
RT= Room temperature,  
Fine= Particle size <250μ,  
Coarse= Particle size >250μ, 
 T=temperature profile,  
rpm= revolutions per min (screw speed),  
* = Temperature of three adjacent zones is 140⁰C,  
WRE= without reverse elements,  
RE= reverse elements. 
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Part – I: Dissolution profiles of extrudates prepare by twin screw extruder without 
using any solvent addition. 
 
[Fig.4.64 Demonstrates percent drug release profile from extrudates prepared without using 
solvent addition]    (n=3)                        
For simplification, the dissolution study was separated into three parts. For simplification, 
each batch was termed by particular letters as mentioned above. The first diagram (See 
fig.4.64) demonstrates dissolution profiles of pure carbamazepine, pure co-crystal and co-
crystals prepared by different batches without any solvent addition. The average percentage 
release of pure carbamazepine (A) was seen to be very low i.e. 33.56% while, the average 
percentage release of pure CBZ: SAC co-crystals prepared by solvent crystallization (B) was 
observed to be more than double that of the pure carbamazepine i.e. 74.18%. It has been 
observed that in the first five minutes the average percentage release of pure carbamazepine 
and pure co-crystal was found to be same. In the case of pure carbamazepine, between 15 min 
and 120 min, the average percentage release of drug remained constant while drug release 
from the co-crystal increased gradually until 120 minutes. Drug release from agglomerates 
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obtained from batch-C was found to be slightly more than pure carbamazepine (36.83%). 
This observed event may be due to the presence of unreacted carbamazepine and saccharin in 
the agglomerates. The agglomerates prepared by batch-D demonstrated drug release up to 
59.28%. It was found that the drug release observed by batch D was more than batch C. But, 
the agglomerates prepared by batch D were not pure co-crystals, and hence drug release was 
found to be less than pure co-crystal (B). The final drug release of agglomerates prepared by 
batch E and F was found to be nearly same i.e. 46.485 and 46.67%, respectively. While, 
agglomerates prepared by batch G (fine particle size) showed negligible increase in drug 
release compared to batch F (coarse particle size). Hence, it can be conclude that variation in 
particle size of the starting components did not affect dissolution of the co-crystals prepared 
by TSE. 
Part– II: Dissolution profile of extrudates prepared by addition of organic solvents like 
methanol and toluene.     
                                                                                
 
[Fig.4.65 Demonstrates drug release profile from extrudates prepared by addition of organic 
solvents like methanol and toluene]                                      (n=3) 
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In fig. 4.65, it has been observed that pure co-crystals prepared by TSE by batch H and I 
demonstrated differences in drug release. The percentage release of both batches was found 
to be same up to first 15 minutes. But, after 30 minutes drug release from co-crystals 
prepared by batch H showed 73.32% which was more compared to drug release obtained by 
batch I (59.99%). The impure co-crystals prepared by toluene addition by batches J and K 
showed drug release slightly more than pure carbamazepine which was 35.91% and 36.54%, 
respectively. 
Part– III: Dissolution profiles of extrudates prepared by using carbamazepine 
dihydrate as a starting component and addition of 5% water  
 
  
[Fig.4.66 Demonstrates drug release profile from extrudates prepared by addition of 5% 
water and carbamazepine dihydrate as a starting product]    (n=3) 
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to 5% water addition to the physical mixture in both batches. However, drug release obtained 
by batches M, O and P was found to be exactly or near to drug release of pure co-crystal by 
solvent crystallization. So it can be conclude that co-crystals prepared using carbamazepine 
dihydrate as a starting component showed identical percent release compared to that prepared 
by 5% water addition.  
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4.4.9 Conclusion  
1. Processing temperature: At and above the eutectic temperature of the physical 
mixture, an intermediate melt phase is produced in the mixing zone which facilitates 
mass transfer. Hence, molecular collisions between API and co-former are increased 
which results in co-crystal growth. The temperature profile nearer to the eutectic 
temperature causes metastable submerged point formation, which force these two 
components together to form a melt. The mixture is then seeded by remaining 
physical mixture which results in successful co-crystallisation.  
2. Co-crystallisation at room temperature: It was observed that pure co-crystals can 
be prepared by twin screw extruder at room temperature in the presence of a polar 
solvent. However, the co-crystallisation process at room temperature leads to an 
unacceptably high torque level which may lead to screw damage. Thus, the method of 
co-crystallisation at room temperature is not ideal as far as processing is concerned. 
3. Shear: Co-crystallisation by TSE is a shear dependent process. It has been found that 
pure co-crystal formation cannot be achieved solely by exposing the API and co-
former at high temperature; however shear is a prerequisite conjointly with 
temperature to effect rearrangement of the bonds which eventually result in hydrogen 
bonded co-crystals. Single screw extrusion does not provide sufficient shear mixing. 
Hence, the twin screw extruder is necessary for co-crystallisation. Moderate shear 
intensity was found to be the optimum shear intensity for co-crystallisation as it 
minimizes the problems of screw blockage, overshooting of torque and degradation of 
components. 
4. Residence time: In the process of co-crystallisation via TSE, total residence time of 
physical mixture does not ensure formation of pure co-crystal. However, the residence 
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time of the mixture in the mixing zone determines the formation of co-crystal. Results 
also supported this fact that as two different experiments was carried out for 
increasing residence time. The first study was carried out by reducing extruder screw 
speed by 50% while; the second study was carried out by using reverse screw 
elements in the screw configuration. But, pure co-crystallisation was only achieved by 
employing reverse screw elements as, it increases residence time of physical mixture 
in the mixing and compression zones. The reduction of screw speed by 50% only 
slows down the process. 
5. Particle size: It was found that particle size of crystalline components did not 
significantly affect on twin screw extruder derived co-crystallisation. 
6. Addition of organic solvents: Addition of a highly polar organic solvent like 
methanol was proved to be an important factor for formation of pure co-crystals. It 
can be concluded that co-crystallisation is independent of minor variations in 
temperature and screw configuration provided that the process is carried out in the 
presence of small amount of a highly polar solvent. It can be concluded that non-polar 
solvents like toluene enhance the co-crystallisation process only in presence of shear 
along with elevated temperature.  
7. Water addition in the physical mixture and use of carbamazepine dihydrate as a 
starting crystalline component: Co-crystals can be prepared by using both 
carbamazepine dihydrate as a starting product and by water addition to the physical 
mixture provided that the screw configuration possesses reverse elements. It was also 
found that the process was not affected by small alterations in screw mixing zones.  
8. Dissolution study: Percent drug release from co-crystals prepared by addition of 
polar solvent showed release profile nearly same to that of co-crystals obtained by 
solvent crystallisation. While, co-crystallisation in presence of toluene and without 
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addition of solvent yield co-crystals which showed less drug release compared to co-
crystals prepared by addition of polar solvent and solvent crystallisation. This may be 
attributed to presence of unreacted component.   
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Future Work: 
Twin screw extruder mediated co-crystallisation is an efficient technology for continuous co-
crystallisation. The main obstacle associated with this technology is high shear along with 
temperature which restricts the processing of thermolabile drugs like carbamazepine. Screw 
configuration, screw speed, temperature profile and solvent addition are key parameters 
which defines successful co-crystallisation.  
The field of co-crystallisation by extrusion is an emerging one; published scientific literature 
is scarce. The following are logical steps which could be taken to enhance understanding: 
1) To identify the compound formed during co-crystallisation in TSE which showed its 
presence by demonstrating an endotherm at 156⁰C in DSC thermogram of extrudates. 
2) To examine the stability of prepared pure co-crystals by twin screw extruder. 
3) To identify the residual solvent content in co-crystals prepared by solvent assisted 
methods. 
4) To perform co-crystallisation experiments using various highly polar solvents at room 
temperature and high temperature profiles. 
5) To carry out co-crystallisation using reverse elements and without solvent addition. 
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